



Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nation-wide cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001148
Article Type:	Research
Date Submitted by the Author:	11-Mar-2012
Complete List of Authors:	Jimenez-Solem, Espen; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Andersen, Jon Traerup; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Petersen, Morten; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Brødbæk, Kasper; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Afzal, Shoaib; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Jensen, Jonas; Gentofte Hospital, Department of Cardiology Gislason, Gunnar; Copenhagen University Hospital Gentofte, Department of Cardiology Torp-Pedersen, Christian; University of Copenhagen, Faculty of Health Sciences; Gentofte Hospital, Department of Cardiology Poulsen, Henrik; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology
Primary Subject Heading:	Pharmacology and therapeutics
Secondary Subject Heading:	Epidemiology, Pharmacology and therapeutics
Keywords:	CLINICAL PHARMACOLOGY, EPIDEMIOLOGY, Fetal medicine < OBSTETRICS, Maternal medicine < OBSTETRICS, Depression & mood disorders < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **EXPOSURE TO SELECTIVE SEROTONINE REUPTAKE INHIBITORS AND THE RISK**
2 **OF CONGENITAL MALFORMATIONS: A NATION-WIDE COHORT-STUDY**

3
4 Espen Jimenez-Solem, M.D.1,2, Jon Trærup Andersen, M.D.1,2, Morten Petersen, M.D.1,2, Kasper
5 Broedbaek, M.D.1,2, Jonas Krogh Jensen, M.B. 3, Shoaib Afzal, M.D.1,2, Gunnar Gislason, M.D.
6 3, Christian Torp-Pedersen D.M.Sc.3,4, Henrik Enghusen Poulsen, D.M.Sc.1,2,4

7
8 1 Laboratory of Clinical Pharmacology Q7642, Rigshospitalet, Copenhagen, Denmark

9 2 Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark

10 3 Department of Cardiology, Gentofte Hospital, Denmark

11 4 Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

12
13 **Correspondence:**

14 M.D. Espen Jimenez-Solem, Laboratory of Clinical Pharmacology Q7642, Rigshospitalet,

15 Tagensevej 20, DK-2200 Copenhagen, Denmark

16 **E-mail:** espen.jimenez.solem@rh.regionh.dk

17 **Phone:** +45 3545 7642

18 **Fax:** +45 3545 2745

19 **Key words:** Pregnancy, antidepressive agents, serotonin uptake inhibitors, congenital

20 malformations, pharmacoepidemiology.

21 **Word count (main text):** 3089

22

1
2
3
4 1 **ABSTRACT**

5
6
7 2 **Objectives**

8
9 3 To analyse the relation between selective serotonin reuptake inhibitor (SSRI) use and major
10
11 4 congenital malformations, with focus on malformations of the heart.

12
13
14 5 **Design**

15
16 6 Register based retrospective nation-wide cohort study, using the Danish Medical Birth Registry.

17
18
19 7 **Setting**

20
21 8 Denmark

22
23
24 9 **Participants**

25
26 10 Pregnant women in Denmark between 1997 and 2009 and their offspring.

27
28
29 11 **Primary outcome measures**

30
31 12 For each SSRI odds ratios for major congenital malformations were estimated using multivariable
32
33 13 logistic regression models for women exposed to an SSRI during the first trimester and for women
34
35 14 pausing exposure during pregnancy.

36
37
38 15 **Results**

39
40
41 16 We identified 848 786 pregnancies; 4183 were exposed to an SSRI throughout the first trimester,
42
43 17 and 806 pregnancies paused exposure during pregnancy. Risks of congenital malformations of the
44
45 18 heart were similar for pregnancies exposed to an SSRI throughout the first trimester; adjusted OR
46
47 19 2.01 (95% CI 1.60-2.53) and for pregnancies pausing SSRI treatment during pregnancy; adjusted
48
49 20 OR 1.85 (95% CI 1.07-3.20). P-value for difference: 0.94. We found similar increased risks of
50
51
52
53
54
55

1
2
3
4 1 specific congenital malformations of the heart for the individual SSRIs. Furthermore, we found no
5
6 2 association with dosage.
7
8

9
10 3 **Conclusions**

11
12 4 The apparent association between SSRI use and congenital malformations of the heart may be
13
14 5 confounded by indications. The moderate absolute risk increase combined with uncertainty for
15
16 6 causality still requires the risk versus benefit to be evaluated in each individual case.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1
2
3
4 **1 ARTICLE SUMMARY**
5
6

7 **2 Article focus**
8

- 9
10 • Relation between SSRIs and congenital malformations
11
12 • Focus on malformations of the heart
13
14 • Focus on women pausing treatment during pregnancy
15
16

17 **6 Key messages**
18

- 19
20 • Risks of congenital malformations of the heart are increased for infants whose mothers were
21 exposed to an SSRI during the first trimester.
22
23 • Risks of congenital malformations of the heart are not different for pregnancies exposed
24 during the first trimester as for pregnancies pausing treatment during pregnancy.
25
26
27
28 • The found risk increases are moderate in absolute terms.
29
30

31 **12 Strengths and limitations of this study**
32

- 33 • Observational study – no causal relations.
34
35 • Nation-wide study, including all live births in the study period.
36
37 • Register based study - no recall bias.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1
2
3
4 1 **ARTICLE**

5
6
7 2 **Introduction**

8
9 3 Depression is common during pregnancy and up to 15% of pregnant women suffer from depression
10
11 4 or depressive symptoms.^{1;2} The most used pharmacological treatment for pregnant women is
12
13 5 selective serotonin reuptake inhibitors (SSRIs).³⁻⁶ Treatment with SSRIs during pregnancy in
14
15 6 Denmark has doubled over a short span of time with 1.4% of pregnancies treated in 2004 compared
16
17 7 to 2.4% in 2007. This rapid increase has also been observed in other countries where the proportion
18
19 8 of pregnant women treated with an SSRI is reported to be even higher than in Denmark.⁴⁻⁸ Several
20
21 9 studies have analysed the consequences of this treatment on pregnancy outcomes, and indicated an
22
23 10 increased risk of congenital malformations^{9;10}, and more notably heart defects.¹¹⁻²¹ However, the
24
25 11 data are conflicting and studies including up to a million pregnancies indicate little risk of
26
27 12 congenital malformations.^{11;13;16-18;22-32} None of these studies have successfully managed to
28
29 13 differentiate between the consequences of the drugs themselves and the underlying disease. Given
30
31 14 the uncertainty of safety and the common use, we performed a nationwide study of the relation
32
33 15 between SSRI use and congenital malformations with focus on congenital heart defects, and
34
35 16 comparison with paused use during pregnancy to account for special characteristics of women using
36
37 17 antidepressants.

38
39
40
41
42
43 18 **Materials and methods**

44
45 19 Through the Danish Medical Birth Registry we identified all pregnancies in Denmark between 1997
46
47 20 and 2009. Their drug redemptions were identified using the Register of Medicinal Product
48
49 21 Statistics. We calculated the associations between exposure to SSRIs and congenital malformations
50
51 22 using multivariable logistic regression adjusted for maternal characteristics.
52
53
54
55

1 Study Population

2 At birth, all Danish citizens are given a unique permanent identification number³³,
3 which enables personalized information to be linked across databases.. Using The Danish Medical
4 Birth Registry we identified 854,008 births between 1997 and 2009. We excluded 5,222 records
5 with missing data on date of birth and pregnancy length. The final cohort consisted of 848,786
6 pregnancies (99.4 % of all pregnancies). The Danish Medical Birth Registry includes data on all
7 births in Denmark since 1973³⁴ and the following information is contained: unique identification
8 numbers of mother and child as well recorded time of gestation, which is based on last menstrual
9 period and ultrasound estimates. We obtained medical treatment from the Danish Register of
10 Medicinal Product Statistics, which, since 1995, has recorded drugs dispensed from Danish
11 pharmacies. Registration is close to perfect due to partial reimbursement by health-care authorities.
12³⁵ For this reason, direct importing by patients is nearly non-existent. The register contains type of
13 drug (International Anatomical Therapeutic Coding (ATC)), date of redemption, quantity dispensed
14 and strength.³⁶ Information on smoking was gathered from the Danish Medical Birth Registry.
15 Individual information on household income and highest attained level of education was gathered
16 from Statistics Denmark.³⁷

17 Outcome Measures

18 Congenital malformations were identified through the Danish National Hospital
19 Register.³⁸ We identified children with congenital malformation within one year of birth and the
20 corresponding grouping according to the European Surveillance of Congenital Anomalies
21 (EUROCAT) classification system guide 1.3.³⁹

1
2
3
4 1 Identification of Exposure

5
6 2 Exposure to the following SSRIs (ATC codes) was identified in the present study:
7
8 3 fluoxetine (N06AB03), citalopram (N06AB04), paroxetine (N06AB05), sertraline (N06AB06), and
9
10 4 escitalopram (N06AB10). Other SSRIs were not included because of low incidence of use (n<50).

11
12
13 5 SSRI prescriptions redeemed during the study period were identified through the
14
15 6 Register of Medicinal Product Statistics. Using the date of prescription, strength and number of
16
17 7 tablets prescribed we performed an estimation of exposure periods and dosages of the individual
18
19 8 SSRIs. We calculated dosage as the average of up to seven prescriptions based on the standard dose
20
21 9 of the individual antidepressant. Calculation of drug exposure periods using this method has been
22
23 10 described previously.⁴⁰

24
25
26
27
28 11 We identified all pregnancies exposed to an SSRI during the first trimester with a
29
30 12 continuous exposure before pregnancy by defining it as exposure between at least one month before
31
32 13 conception and day 84 of pregnancy (last day of the first trimester). Women changing exposure to
33
34 14 another SSRI during the first trimester were not included in the study (n=646). In order to address a
35
36 15 possible confounding by indication we compared our cohort exposed during the first trimester with
37
38 16 a control cohort comprised of women pausing exposure during pregnancy. We defined women with
39
40 17 paused exposure as exposure to an SSRI three to twelve months before conception and one to
41
42 18 twelve months after giving birth, but with no exposure to an SSRI between three months before
43
44 19 conception to one month after giving birth. In addition, they had to be exposed to the same
45
46 20 individual SSRI before and after pregnancy.

47
48
49
50
51 21 We divided the study population into pregnancies exposed to high or low SSRI dose
52
53 22 based on the daily dose values of the individual SSRIs during pregnancy. Doses over the following

1 cut-off values were considered as high doses; 20 mg for citalopram, 10 mg for escitalopram, 20 mg
2 for fluoxetine, 10 mg for paroxetine and 50 mg for sertraline.

3 Statistical Analysis

4 Baseline characteristics were compared with chi-square tests for categorical variables. Risks of
5 malformations were examined with linear logistic regression models. In multivariable analyses we
6 included the mother's age divided into 5 categories: <20, 20-25, 25-30, 30-35, >35 years (0%
7 missing values). Annual gross household income was divided into quartiles (<1% missing values).
8 The highest obtained level of education attained was divided into three groups: low, medium and
9 high, resulting in 4.3% missing values. The number of prior births (parity), including stillbirths, was
10 divided into four classes: 1, 2, 3 and >3 births (<1% missing values). Year of conception was
11 divided into 5 categories (1995-97, 1998-2000, 2001-03, 2004-06, and 2007-09). Smoking was
12 divided into five categories according to the number of daily cigarette: 0, 1-10, 11-20, >20 and
13 unknown (<1% missing values). Body mass index (BMI) was divided into 5 group (<21, 21-25, 26-
14 30, >30). Information on BMI was only available from January 1st 2004, and includes 7% missing
15 values in the period 2004-2009. (Table 1) Records with missing values in the above mentioned
16 categories were not included in the multivariable analyses.

17 Ethics

18 The present study has been approved by The Danish Data Protection Agency (No.
19 2008-41-2517). Retrospective register studies do not require ethical permission in Denmark. Our
20 findings are reported according to strengthening the reporting of observational studies in
21 epidemiology (STROBE).⁴¹

1 Results

2 We identified 4183 pregnancies exposed to an SSRI throughout the first trimester, 806
 3 pregnancies with paused exposure, and 843 797 pregnancies not exposed to an SSRI. 83% of
 4 pregnancies exposed to an SSRI throughout the first trimester went on to redeem a prescription of
 5 an SSRI during the third trimester. Table 1 shows the basic characteristics for women exposed and
 6 to an SSRI, and for unexposed women. Table 2 presents the association between exposure to SSRIs
 7 and major congenital malformation with more than 10 cases, and specific septal congenital defects
 8 of the heart. For information on risks associated with the remaining congenital malformations
 9 please refer to supplement A.

10 **Table 1. Maternal characteristics of women exposed to an SSRI and unexposed**

Characteristic	Exposed to SSRIs		Unexposed	
	First trimester N=4 183	Paused during pregnancy N=806		N=843 797
	N (%)	N (%)	p-value ^a	N (%)
Education			<0.01	
short	1731 (41.38)	372 (46.15)		280447 (33.24)
medium	1119 (26.75)	225 (27.92)		254194 (30.13)
long	1262 (30.17)	193 (23.95)		272380 (32.28)
Missing values	71 (1.7)	16 (1.99)		36776 (4.36)
Annual household income			0.12	
less than \$ 58 335	1320 (31.56)	264 (32.75)		210290 (24.92)
\$ 58 335 - \$ 93 656	1101 (26.32)	222 (27.54)		212110 (25.14)
\$ 93 656 - \$ 119 082	906 (21.66)	185 (22.95)		211436 (25.06)
\$ 119 082 or greater	856 (20.46)	135 (16.75)		207247 (24.56)
Missing values	0 (-)	0 (-)		2714 (0.32)
Age (years)			<0.001	
<20	70 (1.67)	20 (2.48)		23324 (2.76)
21-25	555 (13.27)	122 (15.14)		129059 (15.3)
26-30	1364 (32.61)	269 (33.37)		318664 (37.77)
31-35	1423 (34.02)	295 (36.6)		268959 (31.87)
>35	771 (18.43)	100 (12.41)		102791 (12.18)

Missing values	0 (-)	0 (-)		0 (-)
Parity			<0.001	<0.001
1	1983 (47.41)	282 (34.99)		368168 (43.63)
2	1320 (31.56)	310 (38.46)		308992 (36.62)
>2	833 (19.91)	208 (25.81)		162030 (19.2)
Missing values	47 (1.12)	6 (0.74)		4607 (0.55)
Daily cigarettes			0.53	<0.001
0	2810 (67.18)	532 (66)		660888 (78.32)
1-10	1049 (25.08)	211 (26.18)		128269 (15.2)
11-20	66 (1.58)	11 (1.36)		5294 (0.63)
>20	138 (3.3)	34 (4.22)		20967 (2.48)
No information	118 (2.82)	18 (2.23)		27580 (3.27)
Missing values	2 (0.05)	0 (-)		799 (0.09)
Pre-pregnancy BMI^b			0.89	<0.001
<21	391 (12.23)	66 (12.6)		53500 (13.95)
21-25	1393 (43.59)	233 (44.47)		186428 (48.62)
26-30	705 (22.06)	117 (22.33)		74673 (19.48)
>30	493 (15.43)	74 (14.12)		41652 (10.86)
Missing values	214 (6.7)	35 (6.68)		27161 (7.08)

Data indicate number of pregnancies (N) and percentage (%). ^aChi square tests were used to assess the overall p value for the group comparison with pregnancies exposed to an SSRI during the first trimester. ^bBMI=body mass index. Information on pre-pregnancy BMI was only available for women giving birth after 1. January 2004. Thus this cohort comprises 387 142 pregnancies

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Risk of congenital malformations among women exposed to an SSRI vs. women with no exposure

Outcome	Exposed to any SSRI				p-value ^a	No exposure N=843 797 N (%)
	First trimester N=4183		Paused during pregnancy N=806			
	N (%)	OR (96% CI)	N (%)	OR (96% CI)		
Major malformations	208 (4.97)	1.33 (1.16-1.53)	36 (4.47)	1.27 (0.91-1.78)	0.90	29703 (3.52)
Congenital malformations of the heart	77 (1.84)	2.01 (1.60-2.53)	13 (1.61)	1.85 (1.07-3.20)	0.94	7755 (0.92)
Septal defects	49 (1.17)	2.04 (1.53-2.72)	11 (1.36)	2.56 (1.41-4.64)	0.35	4826 (0.57)
Ventricular septal defects	21 (0.50)	1.62 (1.05-2.50)	9 (1.12)	3.74 (1.93-7.23)	0.97	2803 (0.33)
Atrial septal defects	34 (0.81)	2.60 (1.84-3.68)	6 (0.74)	2.61 (1.17-5.84)	0.74	2490 (0.30)
Congenital malformations of the digestive system	13 (0.31)	1.80 (1.04-3.12)	1 (0.12)	0.75 (0.11-5.35)	0.59	1545 (0.18)
Congenital malformations of the internal urinary system	11 (0.26)	0.84 (0.45-1.57)	-	-	-	2333 (0.28)
Congenital malformations of the external genital organs	19 (0.45)	1.55 (0.99-2.44)	2 (0.25)	0.89 (0.22-3.59)	0.46	2504 (0.30)
Congenital malformations of the limbs	53 (1.27)	0.93 (0.71-1.23)	14 (1.74)	1.37 (0.80-2.32)	0.18	11785 (1.40)

Estimates are presented as Odds Ratios (OR) with 95% confidence intervals (95% CI) ^aP-value for comparison of odds ratios between pregnancies exposed throughout the first trimester and pregnancies with paused exposure during pregnancy. ^bMultivariable logistic regressions are adjusted for mother’s age, parity, income, education, smoking and year of conception.

1
2
3 1 First trimester exposure to any SSRI vs. no exposure
4

5 2 The rate of major congenital malformations among pregnancies exposed to any
6
7 3 SSRI throughout the first trimester was 50 per 1000 pregnancies, compared to 35 pr 1000
8
9 4 unexposed pregnancies (Figure 1). We found an association between SSRI exposure and
10
11 5 major congenital malformations; adjusted OR=1.33 (95% CI, 1.16-1.53) (table 2).
12
13

14
15 6 When analysing the association between exposure to any SSRI and the different
16
17 7 major malformations according to the EUROCAT classification we found a statistically
18
19 8 significant association between exposure to an SSRI and congenital malformations of the
20
21 9 heart; adjusted OR=2.01 (95% CI, 1.60-2.53), and congenital malformations of the digestive
22
23 10 system; adjusted OR=1.80 (95% CI, 1.04-3.12), but not the remaining major congenital
24
25 11 malformations (table 2).
26
27

28
29 12 Paused exposure vs. unexposed
30

31 13 The rate of major congenital malformations among pregnancies pausing
32
33 14 exposure during pregnancy was 45 per 1000 pregnancies (Figure 1). The risk of any major
34
35 15 malformation when pausing exposure to an SSRI during pregnancy was; adjusted OR=1.27
36
37 16 (95% CI, 0.91-1.78) compared to unexposed pregnancies. When estimating the risk of
38
39 17 specific major congenital malformations we found that paused exposure was associated with
40
41 18 congenital malformations of the heart; adjusted OR 1.85 (95% CI, 1.07-3.20) (table 2).
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Rates per 1000 pregnancies of major congenital malformations for infants exposed to selective serotonin reuptake inhibitors in utero




Figure shows number of infants diagnosed with a major malformation per 1000 births. Rates are shown with 95 % confidence intervals.

1
2
3 1 Other Analyses
4

5
6 2 *Exposure to individual SSRIs*
7

8 We found a significant association between major congenital malformations
9 and exposure to citalopram; adjusted OR=1.51 (95% CI, 1.21-1.87), and sertraline; adjusted
10 OR=1.41 (95% CI, 1.03-1.92). Furthermore, we found an association between congenital
11 malformations of the heart and exposure to citalopram; adjusted OR=1.91 (95% CI, 1.31-
12 2.77), fluoxetine; adjusted OR=2.05 (95% CI, 1.27-3.31), and sertraline; adjusted OR=2.73
13 (95% CI, 1.75-4.26). Associations for the remaining major congenital malformations are
14 presented in supplement A.
15
16
17
18
19
20
21
22
23

24 10 *Specific heart defects*
25

26 We performed a sub analysis of the specific congenital septal defects of the
27 heart and their association with exposure to SSRIs and found an association between
28 exposure to any SSRI and septal heart defects; adjusted OR=2.04 (95% CI, 1.53-2.72) (table
29 2). Specifically, ventricular septal defects and atrial septal defects were associated with an
30 increased risk. Increased risk of congenital septal defects was also found for pregnancies with
31 paused exposure; adjusted OR=2.56 (95% CI, 1.41-4.64) (table 2).
32
33
34
35
36
37
38
39

40 For the individual SSRIs we found an association between exposure to all
41 SSRIs, except for escitalopram, and atrial septal defects. Ventricular septal defects was only
42 associated with exposure to sertraline; adjusted OR=3.60 (95% CI, 1.86-6.96), and not the
43 remaining individual SSRIs (supplement A).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 *Other congenital defects*

4
5 2 Studies have reported a possible association between exposure to an SSRI
6
7 3 during pregnancy and omphalocele, anencephaly and craniosynostosis.^{9;10} We found an
8
9 4 association for exposure to an SSRI in the first trimester and craniosynostosis (n=9); adjusted
10
11 5 OR=1.94 (95% CI, 1.00-3.76), but not for omphalocele or anencephaly. For pregnancies with
12
13 6 paused exposure, the association with craniosynostosis (n=3) was; adjusted OR=3.64 (95%
14
15 7 CI, 1.17-11.34).

16
17
18
19 8 *Dosage*

20
21 9 We found an adjusted odds ratio for major malformations: OR 1.39 (95% CI,
22
23 10 1.14-1.68) for low dose exposure and 1.27 (95% CI, 1.03-1.56) for high dose exposure (p for
24
25 11 difference=0.29).

26
27
28
29 12 For the individual major malformations we found similar associations for
30
31 13 pregnancies exposed to low dose and pregnancies exposed to high dose, as for the whole
32
33 14 cohort (Table 3). Analysing the effect of dose as a continuous variable yielded no dose-
34
35 15 response association.

36
37
38
39 ¹⁶**Table 3. Odds Ratios (OR) and 95% confidence intervals (95% CI) for association between congenital malformations among women exposed to low and high doses SSRI during pregnancy.**

Outcome	Low dose SSRI (n=2588)		High dose SSRI (n=1603)		p-value ^b
	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	
Major malformations	121 (4.68)	1.26 (1.05-1.51)	87 (5.43)	1.44 (1.15-1.79)	0.29
Congenital malformations of the heart	44 (1.7)	1.83 (1.35-2.48)	33 (2.06)	2.26 (1.60-3.19)	0.41
Congenital malformations of the digestive system	8 (0.31)	1.78 (0.89-3.58)	5 (0.31)	1.80 (0.75-4.35)	0.99
Congenital malformations of the internal urinary system	6 (0.23)	0.82 (0.37-1.83)	5 (0.31)	0.88 (0.33-2.34)	0.63
Congenital malformations of the external genital organs	10 (0.39)	1.32 (0.71-2.46)	9 (0.56)	1.91 (0.99-3.68)	0.42

Congenital malformations of the limbs	33 (1.28)	0.94 (0.67-1.33)	20 (1.25)	0.91 (0.59-1.42)	0.93
--	-----------	------------------	-----------	------------------	------

^aMultivariable logistic regressions are adjusted for mother's age, parity, income, education, smoking and year of conception. ^bP-value for comparison of odds ratios between pregnancies exposed to low dose SSRI and high dose SSRI.

3

4 *Additional adjustments*

5 In order to identify possible unaccounted confounders we performed additional
6 multivariable analyses including co-medication (psycholeptics, benzodiazepins and
7 antidiabetics) as independent variables in our model. The results showed no considerable
8 change in the estimates or their level of significance compared to our primary analysis.

9 When including body mass index (BMI) as an independent variable in our
10 multivariable model we found the same statistically significant associations for exposure to
11 any SSRI or individual SSRIs, and the specific congenital malformations as our multivariable
12 model not adjusted for BMI. Information on BMI was only available for pregnancies after
13 January 1st 2004, which reduced our cohort to 3196 pregnancies exposed to an SSRI and 383
14 946 with no exposure.

15 *Non-SSRI antidepressants*

16 The association between congenital malformations and exposure to non-SSRI
17 antidepressants: tricyclic antidepressants (ATC N06AA, n=223) and other antidepressants
18 (ATC N06AX, n=831) was; adjusted OR=1.04 (95% CI, 0.53-2.03) and; adjusted OR=0.70
19 (95% CI, 0.47-1.05), respectively. The associations with congenital malformations of the
20 heart were; adjusted OR=1.33 (95% CI, 0.42-4.15) for tricyclic antidepressants and adjusted
21 OR=0.99 (95% CI 0.51-1.91) for other antidepressants.

1 Discussion

2 We performed a retrospective nation-wide cohort study analysing the
3 association between redemption of an SSRI during pregnancy and major congenital
4 malformations. We found an association between exposure to an SSRI during the first
5 trimester and major congenital malformations. More specifically; congenital malformations
6 of the heart (ventricular septal defects and atrial septal defects) and congenital malformations
7 of the digestive system. Furthermore, we found an association between women pausing SSRI
8 exposure during pregnancy and congenital malformations of the heart. Based on findings
9 described in the published literature we will centre the following discussion on major
10 congenital malformations and congenital malformations of the heart for pregnancies exposed
11 to SSRIs.

12 Our study's results are in accordance with two earlier Danish studies^{20;42} based
13 on cohorts comprising only part of the entire nation. A third Danish nation-wide study by
14 Pedersen et al found an increased estimate for major congenital malformations and congenital
15 malformations of the heart, though not statistically significant, in the studied period 1996-
16 2004.¹⁷ The number of exposed women in their study was 1370, compared to ours 4183,
17 which could explain why our estimates reached statistical significance. The study concludes
18 that there is a class effect of SSRIs on heart defects.

19 Several studies have not found an association between exposure to any SSRI
20 and major malformations.^{11;13;16;18;22-32} We find that some of these study are not comparable
21 to ours because most of them are case-control studies, and with cohorts much smaller than
22 ours.^{13;22-29;31} Five of the studies are though similar to ours; based on nation-wide cohorts and

1 national registers, and cohort-sizes comparable to ours. Four are based on Swedish data and
2 are successive updates^{16;18;30;31}, and one on Finnish data.¹¹

3 The latest update of Swedish data found an increased risk of cardiovascular
4 congenital malformations for pregnancies exposed to paroxetine, but not for the remaining
5 individual SSRIs, or SSRI as a group.¹⁸ Information on SSRI exposure was partly based on
6 antenatal interviews which could give rise to recall bias. Furthermore, their analyses were
7 adjusted for BMI. Adjusting our multivariable analysis for BMI had little effect the estimates.

8 The Finnish study found an increased risk of ventricular septal defects for
9 pregnancies exposed to fluoxetine, but not for the remaining individual SSRIs, or SSRI as a
10 group.¹¹ The study is completely based on national registers, like our study. Exposure was
11 though defined as redemption of at least one prescription between one month before
12 pregnancy and birth. This could overestimate the number of exposed women and push
13 estimates towards unity, and explain the lack of association with major congenital
14 malformations, and specifically atrial septal defects.

15 None of the above mentioned studies assessed the risk of congenital
16 malformations for women pausing exposure during pregnancy and thereby addressing the
17 possibility of confounding by indication. Furthermore, neither the Swedish nor the Finnish
18 studies adjusted their analyses for socioeconomic factors which in our study are unevenly
19 distributed between our exposed and unexposed population. Importantly, we believe there are
20 sociodemographic differences between the populations included in these Scandinavian
21 studies compared to ours. Although Denmark resembles both Sweden and Finland,
22 differences in culture and health care policies could account for the discrepancies in our

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 results. Discrepancies between published studies could also be due to the low number of
2 cases, where each case can have a significant effect on the estimate.

3 Congenital malformations of the heart have been associated with exposure to
4 SSRIs in some studies^{10-12;15-18;27;31;42}, in contrast to studies not identifying this
5 association.^{9;13;19;26} Our analyses showed an increased risk of congenital heart defects for the
6 individual SSRIs. Risks of atrial septal defects were furthermore associated with exposure to
7 all individual SSRIs, except for escitalopram. The lack of statistical significance with
8 escitalopram exposure could be due to low statistical power. We found the same increased
9 risks for heart defects for those with paused exposure during pregnancy, which strengthens
10 the assumption of confounding by indication.

11 Although statistically significant, the increased risks associated with SSRI
12 exposure are small in absolute terms. For example, the populations' background risk of atrial
13 septal defects is 0.26 %, and even if we estimate a two-fold risk increase associated with
14 exposure to any SSRI the risk of giving birth to a child with this congenital malformation
15 would be approximately 5 cases for every 1000 births (Figure 1).

16 Strengths and limitations

17 The main weakness is the observational design. We had access to important
18 covariates but it cannot be excluded that unaccounted confounder explain the results. Our
19 study could furthermore be affected by a possible detection bias. Pregnant women exposed to
20 SSRIs are reported to have increased rates of observed malformations, due to increased rates
21 of ultrasound examinations compared to women not treated with SSRIs.⁴³ In contrast,
22 detection of a malformation during an ultrasound examination could lead to pregnancy
23 termination, and thereby decreased rates of malformations among the SSRI exposed. On the

1 other hand, infants of women redeeming prescriptions for SSRIs undergo, in the first year of
2 life, approximately twice as many echocardiograms compared with infants of unexposed
3 women.⁴³ More frequent echocardiograms could increase the risk of heart defect detection, it
4 could also however indicate symptoms of the infant.

5 There is a possibility that we have overestimated SSRI treatment periods, since
6 we cannot adjust for lack of compliance, or the patients' intention of commencing a treatment
7 shortly after drug redemption. However, it has been estimated that the majority of redeemed
8 prescriptions by pregnant women are taken⁴⁴, and compliance in Denmark has been estimated
9 to be 80% for antidepressant treatment during pregnancy.⁴⁵ Furthermore, an overestimation
10 of treatment periods would bias our estimates towards unity. We performed additional
11 analyses defining exposure as redemption of 2 SSRI prescriptions during pregnancy. The
12 results of these analyses, which are not presented, yielded the same statistically significant
13 association as our primary analyses.

14 A main strength is the complete national design including nearly all births in
15 Denmark and the mothers' drug redemptions in the study period. The Register of Medicinal
16 Product Statistics includes approximately 97.5% of all redeemed prescriptions.³⁵ Danish
17 pharmacies are, by law, required to register all redeemed prescriptions as part of the national
18 health care reimbursement scheme. All prescriptions have been redeemed and paid for, which
19 increases the probability of exposure. Recall bias is eliminated since information was
20 recorded prospectively and not based on questionnaires or interviews. Furthermore, to our
21 knowledge, this is the first study to address a possible confounding by indication by assessing
22 risks associated with paused exposure to SSRIs during pregnancy.

1
2
3 1 Conclusion
4

5 2 Our study shows with high confidence a relation between exposure to an SSRI
6
7 3 during the first trimester and risk of congenital malformations of the heart. In addition, we
8
9 4 found a nearly identical risk for women who used an SSRI before and after pregnancy but
10
11 5 discontinued use during pregnancy. We find both associations strong enough to conclude that
12
13 6 risks related to SSRI use during the first trimester are a result of an unaccounted confounder
14
15 7 associated to the redemption of an SSRI prescription. This was sustained by the lack of
16
17 8 relation between dose and risk. However, based on our study's design we cannot rule out an
18
19 9 actual causal relation between redemption of an SSRI and congenital malformations. We
20
21 10 found no relation with non-SSRI antidepressants, which may indicate a particular risk with
22
23 11 SSRIs, but which may also be explained by lack of power.
24
25
26
27

28 12 We therefore conclude that the apparent association between SSRI use and
29
30 13 congenital malformations of the heart may be confounded by indications. The moderate
31
32 14 absolute risk increase combined with uncertainty for causality still requires the risk versus
33
34 15 benefit to be evaluated in each individual case.
35
36
37

38 16 **Acknowledgments**
39

40 17 None to declare.
41
42

43 18 **Competing interests**
44

45 19 All authors declare no support from any organization for the submitted work; no
46
47 20 financial relationships with any organizations that might have an interest in the submitted
48
49 21 work in the previous three years; no other relationships or activities that could appear to have
50
51 22 influenced the submitted work.
52
53
54
55

1
2
3 **1 Funding**
4

5 2 The research project was partially sponsored by the Capital Region of
6
7 3 Copenhagen and the Danish Agency for Science, Technology and Innovation.
8
9

10
11 4
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reference List

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (1) Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. *Obstet Gynecol* 2004;**103**(4):698-709.
- (2) Chatillon O, Even C. [Antepartum depression: Prevalence, diagnosis and treatment.]. *Encephale* 2010;**36**(6):443-451.
- (3) Ververs T, Kaasenbrood H, Visser G, et al. Prevalence and patterns of antidepressant drug use during pregnancy. *Eur J Clin Pharmacol* 2006;**62**(10):863-870.
- (4) Cooper WO, Willy ME, Pont SJ, et al. Increasing use of antidepressants in pregnancy. *Am J Obstet Gynecol* 2007;**196**(6):544-545.
- (5) Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. *Am J Obstet Gynecol* 2008;**198**(2):194-195.
- (6) Alwan S, Reefhuis J, Rasmussen SA, et al. Prevention Study TNBD. Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population. *J Clin Pharmacol* 2011;**51**(2):264-70.
- (7) Bakker MK, Kolling P, van den Berg PB, et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. *Br J Clin Pharmacol* 2008;**65**(4):600-606.
- (8) Wichman CL, Fothergill A, Moore KM, et al. Recent trends in selective serotonin reuptake inhibitor use in pregnancy. *J Clin Psychopharmacol* 2008;**28**(6):714-716.

- 1
2
3 1 (9) Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake
4 inhibitors in pregnancy and the risk of birth defects. *N Engl J Med*
5 2007;**356**(26):2684-2692.
6
7
8
9
10 4 (10) Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-
11 reuptake inhibitors and the risk of birth defects. *N Engl J Med* 2007;**356**(26):2675-
12 2683.
13
14
15
16
17
18 7 (11) Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk
19 for major congenital anomalies. *Obstet Gynecol* 2011;**118**(1):111-120.
20
21
22
23
24 9 (12) Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. First-trimester use of
25 paroxetine and congenital heart defects: a population-based case-control study. *Birth*
26 *Defects Res A Clin Mol Teratol* 2010;**88**(2):94-100.
27
28
29
30
31 12 (13) Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of
32 cardiac malformations in infants: the importance of dosage. *Birth Defects Res B Dev*
33 *Reprod Toxicol* 2007;**80**(1):18-27.
34
35
36
37
38
39 15 (14) Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the
40 prevalence of congenital malformations. *Pharmacoepidemiol Drug Saf*
41 2007;**16**(10):1075-1085.
42
43
44
45
46 18 (15) Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in
47 pregnancy: a prospective, multicentre, controlled, observational study. *Br J Clin*
48 *Pharmacol* 2008;**66**(5):695-705.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 (16) Kallen BA, Otterblad OP. Maternal use of selective serotonin re-uptake inhibitors in
4
5 2 early pregnancy and infant congenital malformations. *Birth Defects Res A Clin Mol*
6
7 3 *Teratol* 2007;**79**(4):301-308.
8
9
10 4 (17) Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake
11
12 5 inhibitors in pregnancy and congenital malformations: population based cohort study.
13
14 6 *BMJ* 2009;**339**:b3569.
15
16
17 7 (18) Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in
18
19 8 pregnancy: an update using Swedish data. *Psychol Med* 2010 Oct;**40**(10):1723-33
20
21
22
23 9 (19) Wichman CL, Moore KM, Lang TR, et al. Congenital Heart Disease Associated With
24
25 10 Selective Serotonin Reuptake Inhibitor Use During Pregnancy. *Mayo Clinic*
26
27 11 *Proceedings* 2009;**84**(1):23-27.
28
29
30
31 12 (20) Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin
32
33 13 reuptake inhibitors and risk of congenital malformations. *Epidemiology*
34
35 14 2006;**17**(6):701-704.
36
37
38
39 15 (21) Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the
40
41 16 prevalence of congenital, specifically cardiac, defects: a meta-analysis of
42
43 17 epidemiological studies. *Birth Defects Res A Clin Mol Teratol* 2010;**88**(3):159-170.
44
45
46 18 (22) Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake
47
48 19 inhibitors in pregnancy. *Obstet Gynecol* 2005;**106**(6):1289-1296.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 (23) Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of
4 the new selective serotonin reuptake inhibitors: a prospective controlled multicenter
5 2 study. *JAMA* 1998;**279**(8):609-610.
6
7
8
9
10
11 4 (24) Ramos E, St-Andre M, Rey E, et al. Duration of antidepressant use during pregnancy
12 and risk of major congenital malformations. *The British Journal of Psychiatry*
13 5 2008;**192**(5):344-350.
14
15
16
17
18 7 (25) Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations in infants
19 following antidepressant exposure in pregnancy: results of a large prospective cohort
20 8 study. *Can J Psychiatry* 2009;**54**(4):242-246.
21
22
23
24
25
26 10 (26) Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations
27 and perinatal events among infants exposed to antidepressant medications during
28 11 pregnancy. *Pharmacoepidemiol Drug Saf* 2007;**16**(10):1086-1094.
29
30
31
32
33
34 13 (27) Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations
35 following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines
36 14 using population-based health data. *Birth Defects Res B Dev Reprod Toxicol*
37 15 2008;**83**(1):68-76.
38
39
40
41
42
43 17 (28) Simon GE, Cunningham ML, Davis RL. Outcomes of Prenatal Antidepressant
44 Exposure. *Am J Psychiatry* 2002;**159**(12):2055-2061.
45
46
47
48
49 19 (29) Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse
50 20 pregnancy outcomes. *Am J Obstet Gynecol* 2006;**194**(4):961-966.
51
52
53
54
55

- 1
2
3 1 (30) Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in
4
5 2 early pregnancy. *Eur J Clin Pharmacol* 1999;**55**(7):503-508.
6
7
8 3 (31) Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant
9
10 4 congenital heart defect. *Reproductive Toxicology* 2006;**21**(3):221-222.
11
12
13 5 (32) Lennestål RM, Kallen BM. Delivery Outcome in Relation to Maternal Use of Some
14
15 6 Recently Introduced Antidepressants. [Article]. *Journal of Clinical*
16
17 7 *Psychopharmacology* 2007;**27**(6):607-613.
18
19
20
21 8 (33) Pedersen CB, Gotzsche H, Møller JO, Mortensen PB. The Danish Civil Registration
22
23 9 System. A cohort of eight million persons. *Dan Med Bull* 2006;**53**(4):441-449.
24
25
26
27 10 (34) Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Dan Med Bull*
28
29 11 1998;**45**(3):320-323.
30
31
32 12 (35) Sørensen HT, Hansen I, Ejlersen E, et al. Identification of patients treated with strong
33
34 13 analgesics: an assessment of two Danish information systems with respect to
35
36 14 epidemiological research. *J Med Syst* 1996;**20**(1):57-65.
37
38
39
40 15 (36) Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. *Dan Med Bull*
41
42 16 1997;**44**(4):445-448.
43
44
45 17 (37) Statistics Denmark. Containing detailed statistical information on the Danish Society.
46
47 18 Available at: <http://www.dst.dk/en>. Accessed March, 2012.
48
49
50 19 (38) Andersen TF, Madsen M, Jørgensen J, et al. The Danish National Hospital Register.
51
52 20 A valuable source of data for modern health sciences. *Dan Med Bull* 1999;**46**(3):263-
53
54 21 268.
55

- 1
2
3 1 (39) European Surveillance of Congenital Anomalies. EUROCAT Guide 1.3 and reference
4
5 2 documents. Newtownabbey Co Antrim: University of Ulster; 2005. Available at:
6
7 3 <http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf>. Accessed March
8
9 4 2012.
- 10
11
12 5 (40) Fosbol EL, Gislason GH, Jacobsen S, et al. The pattern of use of non-steroidal anti-
13
14 6 inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million
15
16 7 people. *Pharmacoepidemiol Drug Saf* 2008;**17**(8):822-833.
- 17
18
19 8 (41) von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
20
21 9 Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting
22
23 10 observational studies. *Lancet* 2007;**370**(9596):1453-1457.
- 24
25
26 11 (42) Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin-reuptake
27
28 12 inhibitors during early pregnancy and risk of congenital malformations: updated
29
30 13 analysis. *Clin Epidemiol* 2010;**2**:29-36.
- 31
32
33 14 (43) Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations:
34
35 15 meta-Analysis and consideration of potential confounding factors. *Clin Ther*
36
37 16 2007;**29**(5):918-926.
- 38
39
40 17 (44) de Jong van den Berg LT, Feenstra N, Sorensen HT, et al.. Improvement of drug
41
42 18 exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and
43
44 19 mother as sources for drug exposure data during pregnancy. EuroMAP Group.
45
46 20 European Medicine and Pregnancy Group. *Teratology* 1999;**60**(1):33-36.
- 47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 (45) Olesen C, Sondergaard C, Thrane N, et al. Do pregnant women report use of
2 dispensed medications? *Epidemiology* 2001;**12**(5):497-501.

For peer review only

Supplement A. Odds Ratios (OR) and 95% confidence intervals (95% CI) for the incidence and risk of congenital malformations among women exposed to individual SSRIs vs. women with no exposure

	SSRI (n=4183)		Citalopram (n=1606)		Escitalopram (n=293)		Fluoxetine (n=928)		Paroxetine (n=568)		Sertraline (n=817)	
	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a
Congenital malformations	208 (4.97)	1.33 (1.16-1.53)	89 (5.54)	89 (5.54-1.51)	8 (2.73)	0.69 (0.34-1.4)	41 (4.42)	1.18 (0.86-1.61)	26 (4.58)	1.25 (0.84-1.85)	44 (5.39)	1.41 (1.03-1.92)
Major	7 (0.17)	1.13 (0.54-2.39)	2 (0.12)	2 (0.12-0.84)	1 (0.34)	2.25 (0.32-16.05)	2 (0.22)	1.44 (0.36-5.79)	1 (0.18)	1.19 (0.17-8.45)	1 (0.12)	0.85 (0.12-6.07)
Of the nervous system	1 (0.02)	0.73 (0.1-5.21)	-	-	0 (0)	-	1 (0.11)	3.22 (0.45-23.03)	0 (0)	-	0 (0)	-
Neural Tube Defects	7 (0.17)	1.43 (0.68-3.01)	5 (0.31)	5 (0.31-2.62)	0 (0)	-	1 (0.11)	0.93 (0.13-6.63)	0 (0)	-	1 (0.12)	1.05 (0.15-7.45)
Of the eye	2 (0.05)	2.36 (0.58-9.61)	0 (0)	-	0 (0)	-	0 (0)	-	1 (0.18)	8.32 (1.16-59.81)	1 (0.12)	6.13 (0.85-44.05)
Of the ear, face and neck	77 (1.84)	2.01 (1.6-2.53)	28 (1.74)	28 (1.74-1.91)	3 (1.02)	1.06 (0.34-3.3)	17 (1.83)	2.05 (1.27-3.31)	8 (1.41)	1.54 (0.77-3.1)	21 (2.57)	2.73 (1.75-4.26)
Of the heart	49 (1.17)	2.04 (1.53-2.72)	17 (1.06)	17 (1.06-1.86)	2 (0.68)	1.12 (0.28-4.51)	9 (0.97)	1.73 (0.89-3.33)	6 (1.06)	1.89 (0.85-4.23)	15 (1.84)	3.09 (1.82-5.25)
Septal defects	21 (0.5)	1.62 (1.05-2.5)	7 (0.44)	7 (0.44-1.41)	0 (0)	0 (0-0)	3 (0.32)	1.03 (0.33-3.2)	2 (0.35)	1.13 (0.28-4.54)	9 (1.1)	3.6 (1.86-6.96)
Ventricular septal defects	34 (0.81)	2.6 (1.84-3.68)	12 (0.75)	12 (0.75-2.41)	1 (0.34)	1.01 (0.14-7.23)	7 (0.75)	2.53 (1.2-5.32)	6 (1.06)	3.51 (1.57-7.87)	8 (0.98)	2.85 (1.35-5.99)
Atrial septal defects	2 (0.05)	1.25 (0.31-5.02)	0 (0)	-	1 (0.34)	8.71 (1.21-62.64)	0 (0)	-	0 (0)	-	1 (0.12)	3.22 (0.45-23.03)
Atrioventricular septal	7 (0.17)	1.41 (0.67-2.98)	2 (0.12)	2 (0.12-1.03)	1 (0.34)	2.66 (0.37-19.02)	1 (0.11)	0.94 (0.13-6.67)	1 (0.18)	1.52 (0.21-10.8)	2 (0.24)	2.09 (0.52-8.38)
Of the respiratory system	6 (0.14)	1.02 (0.46-2.27)	4 (0.25)	4 (0.25-1.8)	0 (0)	-	1 (0.11)	0.76 (0.11-5.4)	0 (0)	0 (0-0)	1 (0.12)	0.88 (0.12-6.24)
Oro-facial clefts	13 (0.31)	1.8 (1.04-3.12)	7 (0.44)	7 (0.44-2.5)	0 (0)	-	2 (0.22)	1.25 (0.31-5)	2 (0.35)	2.09 (0.52-8.39)	2 (0.24)	1.43 (0.36-5.74)
Of the digestive system	1 (0.02)	1.04 (0.14-7.44)	1 (0.06)	1 (0.06-2.54)	0 (0)	-	0 (0)	-	0 (0)	-	0 (0)	-
Abdominal wall defects	11 (0.26)	0.84 (0.45-1.57)	9 (0.56)	9 (0.56-2.02)	0 (0)	-	0 (0)	-	0 (0)	-	2 (0.24)	0.44 (0.06-3.11)
Of the internal urinary system	19 (0.45)	1.55 (0.99-2.44)	8 (0.5)	8 (0.5-1.7)	1 (0.34)	1.08 (0.15-7.67)	3 (0.32)	1.09 (0.35-3.38)	6 (1.06)	3.83 (1.71-8.57)	1 (0.12)	0.41 (0.06-2.93)
Of the external genital organs	53 (1.27)	0.93 (0.71-1.23)	24 (1.49)	24 (1.49-1.13)	1 (0.34)	0.25 (0.04-1.75)	10 (1.08)	0.76 (0.41-1.42)	7 (1.23)	0.91 (0.43-1.92)	11 (1.35)	1 (0.55-1.81)
Of the limbs	8 (0.19)	1.29 (0.64-2.59)	3 (0.19)	3 (0.19-1.25)	1 (0.34)	2.18 (0.31-15.57)	2 (0.22)	1.46 (0.36-5.85)	1 (0.18)	1.2 (0.17-8.55)	1 (0.12)	0.83 (0.12-5.9)
Of the musculoskeletal system	7 (0.17)	1.57 (0.74-3.31)	1 (0.06)	1 (0.06-0.59)	0 (0)	-	1 (0.11)	0.97 (0.14-6.92)	3 (0.53)	4.65 (1.49-14.53)	2 (0.24)	2.35 (0.59-9.45)
Chromosomal abnormalities												

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	9	1.36	4	4	0	-	4	3.08	0	-	1	0.88
Other malformations	(0.22)	(0.68-2.74)	(0.25)	(0.25-1.32)	(0)	-	(0.43)	(1.15-8.23)	(0)	-	(0.12)	(0.12-6.28)
	2	2.78	1	1	0	-	0	-	0	-	1	10.13
And teratogenic syndromes	(0.05)	(0.67-11.6)	(0.06)	(0.06-3.58)	(0)	-	(0)	-	(0)	-	(0.12)	(1.36-75.44)
	1	0.39	0	-	0	-	1	1.79	0	-	0	-
Genetic syndromes	(0.02)	(0.06-2.78)	(0)	-	(0)	-	(0.11)	(0.25-12.76)	(0)	-	(0)	-

Incidence is presented as number of cases (N) with percentages (%). Estimates of multivariable logistic regressions are presented as Odds Ratios (OR) with 95% confidence intervals (95% CI) ^aMultivariable logistic regressions are adjusted for mother’s age, parity, income, education, smoking and year of conception.



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	7,8
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9,10
		(b) Indicate number of participants with missing data for each variable of interest	8
		(c) Summarise follow-up time (eg, average and total amount)	-
Outcome data	15*	Report numbers of outcome events or summary measures over time	9,10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-16
		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	13
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14-16
Discussion			
Key results	18	Summarise key results with reference to study objectives	16,17
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16-21
Generalisability	21	Discuss the generalisability (external validity) of the study results	21
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nation-wide cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001148.R1
Article Type:	Research
Date Submitted by the Author:	10-Apr-2012
Complete List of Authors:	Jimenez-Solem, Espen; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Andersen, Jon Traerup; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Petersen, Morten; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Brødbæk, Kasper; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Afzal, Shoaib; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Jensen, Jonas; Gentofte Hospital, Department of Cardiology Gislason, Gunnar; Copenhagen University Hospital Gentofte, Department of Cardiology Torp-Pedersen, Christian; University of Copenhagen, Faculty of Health Sciences; Gentofte Hospital, Department of Cardiology Poulsen, Henrik; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology
Primary Subject Heading:	Pharmacology and therapeutics
Secondary Subject Heading:	Epidemiology, Cardiovascular medicine, Reproductive medicine, obstetrics and gynaecology
Keywords:	CLINICAL PHARMACOLOGY, EPIDEMIOLOGY, Fetal medicine < OBSTETRICS, Maternal medicine < OBSTETRICS, Depression & mood disorders < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **EXPOSURE TO SELECTIVE SEROTONINE REUPTAKE INHIBITORS AND THE RISK**
2 **OF CONGENITAL MALFORMATIONS: A NATION-WIDE COHORT-STUDY**

3
4 Espen Jimenez-Solem, M.D.1,2, Jon Trærup Andersen, M.D.1,2, Morten Petersen, M.D.1,2, Kasper
5 Broedbaek, M.D.1,2, Jonas Krogh Jensen, M.B. 3, Shoaib Afzal, M.D.1,2, Gunnar Gislason, M.D.
6 3, Christian Torp-Pedersen D.M.Sc.3,4, Henrik Enghusen Poulsen, D.M.Sc.1,2,4

7
8 1 Laboratory of Clinical Pharmacology Q7642, Rigshospitalet, Copenhagen, Denmark

9 2 Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark

10 3 Department of Cardiology, Gentofte Hospital, Denmark

11 4 Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

12
13 **Correspondence:**

14 M.D. Espen Jimenez-Solem, Laboratory of Clinical Pharmacology Q7642, Rigshospitalet,

15 Tagensevej 20, DK-2200 Copenhagen, Denmark

16 **E-mail:** espen.jimenez.solem@rh.regionh.dk

17 **Phone:** +45 3545 7642

18 **Fax:** +45 3545 2745

19 **Key words:** Pregnancy, antidepressive agents, serotonin uptake inhibitors, congenital
20 malformations, pharmacoepidemiology.

21 **Word count (main text):** ~~3089~~3266

22

1
2
3
4 **1 ABSTRACT**

5
6
7 **2 Objectives**

8
9 To analyse the relation between selective serotonin reuptake inhibitor (SSRI) use and major
10
11 congenital malformations, with focus on malformations of the heart.
12

13
14 **5 Design**

15
16 Register based retrospective nation-wide cohort study, using the Danish Medical Birth Registry.
17

18
19
20 **7 Setting**

21
22 Denmark
23

24
25 **9 Participants**

26
27 Pregnant women in Denmark between 1997 and 2009 and their offspring.
28
29

30
31 **11 Primary outcome measures**

32 For each SSRI odds ratios for major congenital malformations were estimated using multivariable
33
34 logistic regression models for women exposed to an SSRI during the first trimester and for women
35
36 ~~pausing with paused~~ exposure during pregnancy.
37
38
39

40
41 **15 Results**

42
43 We identified 848 786 pregnancies; 4183 were exposed to an SSRI throughout the first trimester,
44
45 and 806 pregnancies paused exposure during pregnancy. Risks of congenital malformations of the
46
47 heart were similar for pregnancies exposed to an SSRI throughout the first trimester; adjusted OR
48
49 2.01 (95% CI 1.60-2.53) and for pregnancies ~~pausing with paused~~ SSRI treatment during
50
51 pregnancy; adjusted OR 1.85 (95% CI 1.07-3.20). P-value for difference: 0.94. We found similar
52
53
54
55

1
2
3
4 1 increased risks of specific congenital malformations of the heart for the individual SSRIs.

5
6 2 Furthermore, we found no association with dosage.
7
8

9
10 3 **Conclusions**

11
12 4 The apparent association between SSRI use and congenital malformations of the heart may be

13
14 5 confounded by indications. The moderate absolute risk increase combined with uncertainty for

15
16 6 causality still requires the risk versus benefit to be evaluated in each individual case.
17
18

19
20 7
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 ARTICLE SUMMARY

2 Article focus

- 3 • Relation between SSRIs and congenital malformations
- 4 • Focus on malformations of the heart
- 5 • Focus on women pausing-with paused treatment during pregnancy

6 Key messages

- 7 • Risks of congenital malformations of the heart are increased for infants whose mothers were
8 exposed to an SSRI during the first trimester.
- 9 • Risks of congenital malformations of the heart are not different for pregnancies exposed
10 during the first trimester as for pregnancies pausing-with paused treatment during
11 pregnancy.
- 12 • The found risk increases are moderate in absolute terms.

13 Strengths and limitations of this study

- 14 • Observational study – no causal relations.
- 15 • Nation-wide study, including all live births in the study period.
- 16 • Register based study - no recall bias.

ARTICLE

Introduction

Depression is common during pregnancy and up to 15% of pregnant women suffer from depression or depressive symptoms.^{1;2} The most used pharmacological treatment for pregnant women is selective serotonin reuptake inhibitors (SSRIs).³⁻⁶ Treatment with SSRIs during pregnancy in Denmark has doubled over a short span of time with 1.4% of pregnancies treated in 2004 compared to 2.4% in 2007. This rapid increase has also been observed in other countries where the proportion of pregnant women treated with an SSRI is reported to be even higher than in Denmark.⁴⁻⁸ Several studies have analysed the consequences of this treatment on pregnancy outcomes, and indicated an increased risk of congenital malformations^{9;10}, and more notably heart defects.¹¹⁻²¹ However, the data are conflicting^{11;13;16-18;22-32} and studies including up to a million pregnancies indicate little risk of congenital malformations^{11;16;18;30;31 11;13;16-18;22-32}. None of these studies have successfully managed to differentiate between the consequences of the drugs themselves and the underlying disease. Given the uncertainty of safety and the common use, we performed a nationwide study of the relation between SSRI use and congenital malformations with focus on congenital heart defects, and comparison with paused use during pregnancy to account for special characteristics of women using antidepressants.

Materials and methods

Through the Danish Medical Birth Registry we identified all pregnancies in Denmark between 1997 and 2009. Their drug redemptions were identified using the Register of Medicinal Product Statistics. We calculated the associations between exposure to SSRIs and congenital malformations using multivariable logistic regression adjusted for maternal characteristics.

1 Study Population

2 At birth, all Danish citizens are given a unique permanent identification number³³,
3 which enables personalized information to be linked across databases.. Using The Danish Medical
4 Birth Registry we identified 854,008 births between 1997 and 2009. We excluded 5,222 records
5 with missing data on date of birth and pregnancy length. The final cohort consisted of 848,786
6 pregnancies (99.4 % of all pregnancies). The Danish Medical Birth Registry includes data on all
7 births in Denmark since 1973³⁴ and the following information is contained: unique identification
8 numbers of mother and child as well recorded time of gestation, which is based on last menstrual
9 period and ultrasound estimates. We obtained medical treatment from the Danish Register of
10 Medicinal Product Statistics, which, since 1995, has recorded drugs dispensed from Danish
11 pharmacies. Registration is close to perfect due to partial reimbursement by health-care authorities.
12 ³⁵ For this reason, direct importing by patients is nearly non-existent. The register contains type of
13 drug (International Anatomical Therapeutic Coding (ATC)), date of redemption, quantity dispensed
14 and strength.³⁶ Information on smoking was gathered from the Danish Medical Birth Registry.
15 Individual information on household income and highest attained level of education was gathered
16 from Statistics Denmark.³⁷

17 Outcome Measures

18 Congenital malformations were identified through the Danish National Hospital
19 Register.³⁸ We identified children with congenital malformation within one year of birth and the
20 corresponding grouping according to the European Surveillance of Congenital Anomalies
21 (EUROCAT) classification system guide 1.3.³⁹

1
2
3
4 1 Identification of Exposure

5
6 2 Exposure to the following SSRIs (ATC codes) was identified in the present study:
7
8 3 fluoxetine (N06AB03), citalopram (N06AB04), paroxetine (N06AB05), sertraline (N06AB06), and
9
10 4 escitalopram (N06AB10). Other SSRIs were not included because of low incidence of use (n<50).

11
12
13
14 5 SSRI prescriptions redeemed during the study period were identified through the
15
16 6 Register of Medicinal Product Statistics. Using the date of prescription, strength and number of
17
18 7 tablets prescribed we performed an estimation of exposure periods and dosages of the individual
19
20 8 SSRIs. We calculated dosage as the average of up to seven prescriptions based on the standard dose
21
22 9 of the individual antidepressant. Calculation of drug exposure periods using this method has been
23
24
25 10 described previously.⁴⁰

26
27
28 11 We identified all pregnancies exposed to an SSRI during the first trimester with a
29
30 12 continuous exposure before pregnancy by defining it as exposure between at least one month before
31
32 13 conception and day 84 of pregnancy (last day of the first trimester). Women changing exposure to
33
34 14 another SSRI during the first trimester were not included in the study (n=646). In order to address a
35
36 15 possible confounding by indication we compared our cohort exposed during the first trimester with
37
38
39 16 a control cohort comprised of women pausing with paused exposure during pregnancy. We defined
40
41 17 women with paused exposure as exposure to an SSRI three to twelve months before conception and
42
43 18 one to twelve months after giving birth, but with no exposure to an SSRI between three months
44
45 19 before conception to one month after giving birth. In addition, they had to be exposed to the same
46
47
48 20 individual SSRI before and after pregnancy to ensure comparability with women exposed during
49
50 21 the first trimester.

1 We divided the study population into pregnancies exposed to high or low SSRI dose
2 based on the recommended daily dose values of the individual SSRIs during pregnancy. Doses over
3 the following cut-off values were considered as high doses; 20 mg for citalopram, 10 mg for
4 escitalopram, 20 mg for fluoxetine, ~~20~~40 mg for paroxetine and 50 mg for sertraline.

5 Statistical Analysis

6 Baseline characteristics were compared with chi-square tests for categorical variables. Risks of
7 malformations were examined with linear logistic regression models. In multivariable analyses we
8 included the mother's age divided into 5 categories: <20, 20-25, 25-30, 30-35, >35 years (0%
9 missing values). Annual gross household income was divided into quartiles (<1% missing values).
10 The highest obtained level of education attained was divided into three groups: low, medium and
11 high, resulting in 4.3% missing values. The number of prior births (parity), including stillbirths, was
12 divided into four classes: 1, 2, 3 and >3 births (<1% missing values). Year of conception was
13 divided into 5 categories (1995-97, 1998-2000, 2001-03, 2004-06, and 2007-09). Smoking was
14 divided into five categories according to the number of daily cigarette: 0, 1-10, 11-20, >20 and
15 unknown (<1% missing values). Body mass index (BMI) was divided into 5 group (<21, 21-25, 26-
16 30, >30). Information on BMI was only available from January 1st 2004, and includes 7% missing
17 values in the period 2004-2009. (Table 1) Records with missing values in the above mentioned
18 categories were not included in the multivariable analyses.

19 Ethics

20 The present study has been approved by The Danish Data Protection Agency (No.
21 2008-41-2517). Retrospective register studies do not require ethical permission in Denmark. Our
22 findings are reported according to strengthening the reporting of observational studies in
23 epidemiology (STROBE).⁴¹

1 Results

2 We identified 4183 pregnancies exposed to an SSRI throughout the first trimester, 806
 3 pregnancies with paused exposure, and 843 797 pregnancies not exposed to an SSRI. 83% of
 4 pregnancies exposed to an SSRI throughout the first trimester went on to redeem a prescription of
 5 an SSRI during the third trimester. Table 1 shows the basic characteristics for women exposed and
 6 to an SSRI, and for unexposed women. Table 2 presents the association between exposure to SSRIs
 7 and major congenital malformation with more than 10 cases, and specific septal congenital defects
 8 of the heart. For information on risks associated with the remaining congenital malformations
 9 please refer to supplement A.

10 **Table 1. Maternal characteristics of women exposed to an SSRI and unexposed**

Characteristic	Exposed to SSRIs		p-value ^a	Unexposed	
	First trimester N=4 183 N (%)	Paused during pregnancy N=806 N (%)		N (%)	p-value ^a
Education			<0.01		<0.001
short	1731 (41.38)	372 (46.15)		280447 (33.24)	
medium	1119 (26.75)	225 (27.92)		254194 (30.13)	
long	1262 (30.17)	193 (23.95)		272380 (32.28)	
Missing values	71 (1.70)	16 (1.99)		36776 (4.36)	
Annual household income			0.12		<0.001
less than \$ 58 335	1320 (31.56)	264 (32.75)		210290 (24.92)	
\$ 58 335 - \$ 93 656	1101 (26.32)	222 (27.54)		212110 (25.14)	
\$ 93 656 - \$ 119 082	906 (21.66)	185 (22.95)		211436 (25.06)	
\$ 119 082 or greater	856 (20.46)	135 (16.75)		207247 (24.56)	
Missing values	0 (-)	0 (-)		2714 (0.32)	
Age (years)			<0.001		<0.001
<20	70 (1.67)	20 (2.48)		23324 (2.76)	
21-25	555 (13.27)	122 (15.14)		129059 (15.30)	
26-30	1364 (32.61)	269 (33.37)		318664 (37.77)	
31-35	1423 (34.02)	295 (36.60)		268959 (31.87)	
>35	771 (18.43)	100 (12.41)		102791 (12.18)	

Missing values	0 (-)	0 (-)		0 (-)
Parity			<0.001	<0.001
1	1983 (47.41)	282 (34.99)		368168 (43.63)
2	1320 (31.56)	310 (38.46)		308992 (36.62)
>2	833 (19.91)	208 (25.81)		162030 (19.20)
Missing values	47 (1.12)	6 (0.74)		4607 (0.55)
Daily cigarettes			0.53	<0.001
0	2810 (67.18)	532 (66)		660888 (78.32)
1-10	1049 (25.08)	211 (26.18)		128269 (15.2)
11-20	66 (1.58)	11 (1.36)		5294 (0.63)
>20	138 (3.30)	34 (4.22)		20967 (2.48)
No information	118 (2.82)	18 (2.23)		27580 (3.27)
Missing values	2 (0.05)	0 (-)		799 (0.09)
Pre-pregnancy BMI^b			0.89	<0.001
<21	391 (12.23)	66 (12.60)		53500 (13.95)
21-25	1393 (43.59)	233 (44.47)		186428 (48.62)
26-30	705 (22.06)	117 (22.33)		74673 (19.48)
>30	493 (15.43)	74 (14.12)		41652 (10.86)
Missing values	214 (6.70)	35 (6.68)		27161 (7.08)

Data indicate number of pregnancies (N) and percentage (%). ^aChi square tests were used to assess the overall p value for the group comparison with pregnancies exposed to an SSRI during the first trimester. ^bBMI=body mass index. Information on pre-pregnancy BMI was only available for women giving birth after 1. January 2004. Thus this cohort comprises 387 142 pregnancies

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Risk of congenital malformations among women exposed to an SSRI vs. women with no exposure

Outcome	Exposed to any SSRI				p-value ^a	No exposure N=843 797 N (%)
	First trimester N=4183		Paused during pregnancy N=806			
	N (%)	OR (96% CI)	N (%)	OR (96% CI)		
Major malformations	208 (4.97)	1.33 (1.16-1.53)	36 (4.47)	1.27 (0.91-1.78)	0.90	29703 (3.52)
Congenital malformations of the heart	77 (1.84)	2.01 (1.60-2.53)	13 (1.61)	1.85 (1.07-3.20)	0.94	7755 (0.92)
Septal defects	49 (1.17)	2.04 (1.53-2.72)	11 (1.36)	2.56 (1.41-4.64)	0.35	4826 (0.57)
Ventricular septal defects	21 (0.50)	1.62 (1.05-2.50)	9 (1.12)	3.74 (1.93-7.23)	0.97	2803 (0.33)
Atrial septal defects	34 (0.81)	2.60 (1.84-3.68)	6 (0.74)	2.61 (1.17-5.84)	0.74	2490 (0.30)
Congenital malformations of the digestive system	13 (0.31)	1.80 (1.04-3.12)	1 (0.12)	0.75 (0.11-5.35)	0.59	1545 (0.18)
Congenital malformations of the internal urinary system	11 (0.26)	0.84 (0.45-1.57)	-	-	-	2333 (0.28)
Congenital malformations of the external genital organs	19 (0.45)	1.55 (0.99-2.44)	2 (0.25)	0.89 (0.22-3.59)	0.46	2504 (0.30)
Congenital malformations of the limbs	53 (1.27)	0.93 (0.71-1.23)	14 (1.74)	1.37 (0.80-2.32)	0.18	11785 (1.40)

Estimates are presented as Odds Ratios (OR) with 95% confidence intervals (95% CI) ^aP-value for comparison of odds ratios between pregnancies exposed throughout the first trimester and pregnancies with paused exposure during pregnancy. ^bMultivariable logistic regressions are adjusted for mother’s age, parity, income, education, smoking and year of conception.

1
2
3 1 First trimester exposure to any SSRI vs. no exposure
4


5 2 The rate of major congenital malformations among pregnancies exposed to any
6
7 3 SSRI throughout the first trimester was 50 per 1000 pregnancies, compared to 35 pr 1000
8
9 4 unexposed pregnancies (Figure 1). We found an association between SSRI exposure and
10
11 5 major congenital malformations; adjusted OR=1.33 (95% CI, 1.16-1.53) (table 2).
12
13

14
15 6 When analysing the association between exposure to any SSRI and the different
16
17 7 major malformations according to the EUROCAT classification we found a statistically
18
19 8 significant association between exposure to an SSRI and congenital malformations of the
20
21 9 heart; adjusted OR=2.01 (95% CI, 1.60-2.53), and congenital malformations of the digestive
22
23 10 system; adjusted OR=1.80 (95% CI, 1.04-3.12), but not the remaining major congenital
24
25 11 malformations (table 2).
26
27
28

29 12 Paused exposure vs. unexposed
30

31 13 The rate of major congenital malformations among pregnancies pausing-with
32
33 14 paused exposure during pregnancy was 45 per 1000 pregnancies (Figure 1). The risk of any
34
35 15 major malformation for women with when-paused exposure to an SSRI during pregnancy
36
37 16 was; adjusted OR=1.27 (95% CI, 0.91-1.78) compared to unexposed pregnancies. When
38
39 17 estimating the risk of specific major congenital malformations we found that paused exposure
40
41 18 was associated with congenital malformations of the heart; adjusted OR 1.85 (95% CI, 1.07-
42
43 19 3.20) (table 2).
44
45
46
47
48
49
50
51
52
53
54
55

Figure 1. Rates per 1000 pregnancies of major congenital malformations for infants exposed to selective serotonin reuptake inhibitors in utero



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure shows number of infants diagnosed with a major malformation per 1000 births. Rates are shown with 95 % confidence intervals.

1
2
3 1 Other Analyses
4

5
6 2 *Exposure to individual SSRIs*
7

8 We found a significant association between major congenital malformations
9 and exposure to citalopram; adjusted OR=1.51 (95% CI, 1.21-1.87), and sertraline; adjusted
10 OR=1.41 (95% CI, 1.03-1.92). Furthermore, we found an association between congenital
11 malformations of the heart and exposure to citalopram; adjusted OR=1.91 (95% CI, 1.31-
12 2.77), fluoxetine; adjusted OR=2.05 (95% CI, 1.27-3.31), and sertraline; adjusted OR=2.73
13 (95% CI, 1.75-4.26). Associations for the remaining major congenital malformations are
14 presented in supplement A.
15
16
17
18
19
20
21
22
23

24 10 *Specific heart defects*
25

26 We performed a sub analysis of the specific congenital septal defects of the
27 heart and their association with exposure to SSRIs and found an association between
28 exposure to any SSRI and septal heart defects; adjusted OR=2.04 (95% CI, 1.53-2.72) (table
29 2). Specifically, ventricular septal defects and atrial septal defects were associated with an
30 increased risk. Increased risk of congenital septal defects was also found for pregnancies with
31 paused exposure; adjusted OR=2.56 (95% CI, 1.41-4.64) (table 2).
32
33
34
35
36
37
38
39
40

41 For the individual SSRIs we found an association between exposure to all
42 SSRIs, except for escitalopram, and atrial septal defects. Ventricular septal defects was only
43 associated with exposure to sertraline; adjusted OR=3.60 (95% CI, 1.86-6.96), and not the
44 remaining individual SSRIs (supplement A).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 *Other congenital defects*

4
5 2 Studies have reported a possible association between exposure to an SSRI
6
7 3 during pregnancy and omphalocele, anencephaly and craniosynostosis.^{9:10} We found an
8
9 4 association for exposure to an SSRI in the first trimester and craniosynostosis (n=9); adjusted
10
11 5 OR=1.94 (95% CI, 1.00-3.76), but not for omphalocele or anencephaly. For pregnancies with
12
13 6 paused exposure, the association with craniosynostosis (n=3) was; adjusted OR=3.64 (95%
14
15 7 CI, 1.17-11.34).

16
17
18
19 8 *Dosage*

20
21 9 We found an adjusted odds ratio for major malformations: OR 1.39 (95% CI,
22
23 10 1.14-1.68) for low dose exposure and 1.27 (95% CI, 1.03-1.56) for high dose exposure (p for
24
25 11 difference=0.29).

26
27
28
29 12 For the individual major malformations we found similar associations for
30
31 13 pregnancies exposed to low dose and pregnancies exposed to high dose, as for the whole
32
33 14 cohort (Table 3). Analysing the effect of dose as a continuous variable yielded no dose-
34
35 15 response association.

36
37
38
39 **Table 3. Odds Ratios (OR) and 95% confidence intervals (95% CI) for association between congenital**
40 **malformations among women exposed to low and high doses SSRI during pregnancy.**

Outcome	Low dose SSRI (n=2588)		High dose SSRI (n=1603)		p-value ^b
	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	
Major malformations	121 (4.68)	1.26 (1.05-1.51)	87 (5.43)	1.44 (1.15-1.79)	0.29
Congenital malformations of the heart	44 (1.70)	1.83 (1.35-2.48)	33 (2.06)	2.26 (1.60-3.19)	0.41
Congenital malformations of the digestive system	8 (0.31)	1.78 (0.89-3.58)	5 (0.31)	1.80 (0.75-4.35)	0.99
Congenital malformations of the internal urinary system	6 (0.23)	0.82 (0.37-1.83)	5 (0.31)	0.88 (0.33-2.34)	0.63
Congenital malformations of the external genital organs	10 (0.39)	1.32 (0.71-2.46)	9 (0.56)	1.91 (0.99-3.68)	0.42

Congenital malformations of the limbs

33 (1.28) 0.94 (0.67-1.33) 20 (1.25) 0.91 (0.59-1.42) 0.93

^aMultivariable logistic regressions are adjusted for mother's age, parity, income, education, smoking and year of conception. ^bP-value for comparison of odds ratios between pregnancies exposed to low dose SSRI and high dose SSRI.

3

4 *Additional adjustments*

5 In order to identify possible unaccounted confounders we performed additional
6 multivariable analyses including co-medication (psycholeptics; [ATC code A05,-](#)
7 ~~benzodiazepins~~ and antidiabetics; [ATC code A10](#)) as independent variables in our model.
8 The results showed no considerable change in the estimates or their level of significance
9 compared to our primary analysis ([Supplement B](#)).

10 When including body mass index (BMI) as an independent variable in our
11 multivariable model we found the same statistically significant associations for exposure to
12 any SSRI or individual SSRIs, and the specific congenital malformations as our multivariable
13 model not adjusted for BMI. Information on BMI was only available for pregnancies after
14 January 1st 2004, which reduced our cohort to 3196 pregnancies exposed to an SSRI and 383
15 946 with no exposure.

16 *Non-SSRI antidepressants*

17 The association between congenital malformations and exposure to non-SSRI
18 antidepressants: tricyclic antidepressants (ATC N06AA, n=223) and other antidepressants
19 (ATC N06AX, n=831) was; adjusted OR=1.04 (95% CI, 0.53-2.03) and; adjusted OR=0.70
20 (95% CI, 0.47-1.05), respectively. The associations with congenital malformations of the
21 heart were; adjusted OR=1.33 (95% CI, 0.42-4.15) for tricyclic antidepressants and adjusted
22 OR=0.99 (95% CI 0.51-1.91) for other antidepressants.

1 Discussion

2 We performed a retrospective nation-wide cohort study analysing the
3 association between redemption of an SSRI during pregnancy and major congenital
4 malformations. We found an association between exposure to an SSRI during the first
5 trimester and major congenital malformations. More specifically; congenital malformations
6 of the heart (ventricular septal defects and atrial septal defects) and congenital malformations
7 of the digestive system. Furthermore, we found an association between women pausing with
8 SSRI-paused SSRI exposure during pregnancy and congenital malformations of the heart.
9 Based on findings described in the published literature we will centre the following
10 discussion on major congenital malformations and congenital malformations of the heart for
11 pregnancies exposed to SSRIs.

12 Our study's results are in accordance with two earlier Danish studies^{20;42} based
13 on cohorts comprising only part of the entire nation. A third Danish nation-wide study by
14 Pedersen et al found an increased estimate for major congenital malformations and congenital
15 malformations of the heart, though not statistically significant, in the studied period 1996-
16 2004.¹⁷ The number of exposed women in their study was 1370, compared to ours 4183,
17 which could explain why our estimates reached statistical significance. The study concludes
18 that there is a class effect of SSRIs on heart defects.

19 Several studies have not found an association between exposure to any SSRI
20 and major malformations overall.^{11;13;16;18;22-32} We find that some of these study are not
21 comparable to ours because most of them are case-control studies, and with cohorts much
22 smaller than ours.^{13;22-29;31} Five of the studies are though similar to ours; based on nation-

1 wide cohorts and national registers, and cohort-sizes comparable to ours. Four are based on
2 Swedish data and are successive updates^{16;18;30;31}, and one on Finnish data.¹¹

3 The latest update of Swedish data found an increased risk of cardiovascular
4 congenital malformations for pregnancies exposed to paroxetine, but not for the remaining
5 individual SSRIs, or SSRI as a group.¹⁸ Information on SSRI exposure was partly based on
6 antenatal interviews which could, although unlikely, give rise to recall bias. Furthermore,
7 their analyses were adjusted for BMI. Adjusting our multivariable analysis for BMI had little
8 effect the estimates.

9 The Finnish study found an increased risk of ventricular septal defects for
10 pregnancies exposed to fluoxetine, but not for the remaining individual SSRIs, or SSRI as a
11 group.¹¹ The study is completely based on national registers, like our study. Exposure was
12 though defined as redemption of at least one prescription between one month before
13 pregnancy and ~~birth~~the end of the first trimester. This could ~~under~~overestimate the number of
14 exposed women if prescriptions for an SSRI were redeemed just before and after this chosen
15 period. This could indicate continuous exposure during the first trimester and ~~and~~ push
16 estimates towards unity, and, in theory, explain the lack of association with major congenital
17 malformations, and specifically atrial septal defects.

18 None of the above mentioned studies assessed the risk of congenital
19 malformations for women ~~pausing with paused~~ exposure during pregnancy and thereby
20 addressing the possibility of confounding by indication. Furthermore, neither the Swedish nor
21 the Finnish studies adjusted their analyses for socioeconomic factors which in our study are
22 unevenly distributed between our exposed and unexposed population. Importantly, we
23 believe there are sociodemographic differences between the populations included in these

1 Scandinavian studies compared to ours. Although Denmark resembles both Sweden and
2 Finland, differences in culture and health care policies could account for the discrepancies in
3 our results. Discrepancies between published studies could also be due to the low number of
4 cases, where each case can have a significant effect on the estimate.

5 Congenital malformations of the heart have been associated with exposure to
6 SSRIs in some studies^{10-12;15-18;27;31;42}, in contrast to studies not identifying this
7 association.^{9;13;19;26} Our analyses showed an increased risk of congenital heart defects for the
8 individual SSRIs. Risks of atrial septal defects were furthermore associated with exposure to
9 all individual SSRIs, except for escitalopram. The lack of statistical significance with
10 escitalopram exposure could be due to low statistical power. We found the same increased
11 risks for heart defects for those with paused exposure during pregnancy, which strengthens
12 the assumption of confounding by indication.

13 Although statistically significant, the increased risks associated with SSRI
14 exposure are small in absolute terms. For example, the populations' background risk of atrial
15 septal defects is 0.26 %, and even if we estimate a two-fold risk increase associated with
16 exposure to any SSRI the risk of giving birth to a child with this congenital malformation
17 would be approximately 5 cases for every 1000 births (Figure 1).

18 Strengths and limitations

19 The main weakness is the observational design. We had access to important
20 covariates but it cannot be excluded that unaccounted confounder explain the results. Our
21 study could furthermore be affected by a possible detection bias. Pregnant women exposed to
22 SSRIs are reported to have increased rates of observed malformations, due to increased rates
23 of ultrasound examinations compared to women not treated with SSRIs.⁴³ In contrast,

1 detection of a malformation during an ultrasound examination could lead to pregnancy
2 termination, and thereby decreased rates of malformations among the SSRI exposed. On the
3 other hand, infants of women redeeming prescriptions for SSRIs undergo, in the first year of
4 life, approximately twice as many echocardiograms compared with infants of unexposed
5 women.⁴³ More frequent echocardiograms could increase the risk of heart defect detection
6 and give rise to information bias (diagnostic suspicion bias). This bias could partly explain
7 our findings. On the other hand, more frequent echocardiograms could indicate a more severe
8 symptomatology among the exposed children due to an unaccounted factor. ,it could also
9 however indicate symptoms of the infant.

10 Importantly, information on indication for elective termination of pregnancies
11 was not available in our databases. If pregnant women exposed to an SSRI had a higher rate
12 of provoked abortions due to severe malformations it could mask a possible teratogenic effect
13 of the drugs.

14 There is a possibility that we have overestimated SSRI treatment periods, since
15 we cannot adjust for lack of compliance, or the patients' intention of commencing a treatment
16 shortly after drug redemption. However, it has been estimated that the majority of redeemed
17 prescriptions by pregnant women are taken⁴⁴, and compliance in Denmark has been estimated
18 to be 80% for antidepressant treatment during pregnancy.⁴⁵ Furthermore, an overestimation
19 of treatment periods would bias our estimates towards unity. We performed additional
20 analyses defining exposure as redemption of 2 SSRI prescriptions during pregnancy. The
21 results of these analyses, which are not presented, yielded the same statistically significant
22 association as our primary analyses.

1 A main strength is the complete national design including nearly all births in
2 Denmark and the mothers' drug redemptions in the study period. The Register of Medicinal
3 Product Statistics includes approximately 97.5% of all redeemed prescriptions.³⁵ Danish
4 pharmacies are, by law, required to register all redeemed prescriptions as part of the national
5 health care reimbursement scheme. All prescriptions have been redeemed and paid for, which
6 increases the probability of exposure. Recall bias is eliminated since information was
7 recorded prospectively and not based on questionnaires or interviews. Furthermore, to our
8 knowledge, this is the first study to address a possible confounding by indication by assessing
9 risks associated with paused exposure to SSRIs during pregnancy.

10 Conclusion

11 Our study shows with high confidence a relation between exposure to an SSRI
12 during the first trimester and risk of congenital malformations of the heart. In addition, we
13 found a nearly identical risk for women who used an SSRI before and after pregnancy but
14 discontinued use during pregnancy. We find both associations strong enough to conclude that
15 risks related to SSRI use during the first trimester are a result of an unaccounted confounder
16 associated to the redemption of an SSRI prescription. This was sustained by the lack of
17 relation between dose and risk. A possible explanation could be information bias, because
18 children of women redeeming an SSRI are more likely to undergo an echocardiogram during
19 the first year of life. However, based on our study's design we cannot rule out an actual
20 causal relation between redemption of an SSRI and congenital malformations. We found no
21 relation with non-SSRI antidepressants, which may indicate a particular risk with SSRIs, but
22 which may also be explained by lack of power.

1
2
3 1 We therefore conclude that the apparent association between SSRI use and
4
5 2 congenital malformations of the heart may be confounded by indications. The moderate
6
7 3 absolute risk increase combined with uncertainty for causality still requires the risk versus
8
9 4 benefit to be evaluated in each individual case.

12 **Acknowledgments**

13
14
15 6 None to declare.

17 **Competing interests**

18
19
20 8 All authors declare no support from any organization for the submitted work; no
21
22 9 financial relationships with any organizations that might have an interest in the submitted
23
24 10 work in the previous three years; no other relationships or activities that could appear to have
25
26 11 influenced the submitted work.

28 **Funding**

29
30
31
32 13 The research project was partially sponsored by the Capital Region of
33
34 14 Copenhagen and the Danish Agency for Science, Technology and Innovation.

- 1
2
3 1 (9) Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake
4 inhibitors in pregnancy and the risk of birth defects. *N Engl J Med*
5 2007;**356**(26):2684-2692.
6
7
8
9
10 4 (10) Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-
11 reuptake inhibitors and the risk of birth defects. *N Engl J Med* 2007;**356**(26):2675-
12 2683.
13
14
15
16
17 7 (11) Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk
18 for major congenital anomalies. *Obstet Gynecol* 2011;**118**(1):111-120.
19
20
21
22
23 9 (12) Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. First-trimester use of
24 paroxetine and congenital heart defects: a population-based case-control study. *Birth*
25 *Defects Res A Clin Mol Teratol* 2010;**88**(2):94-100.
26
27
28
29
30
31 12 (13) Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of
32 cardiac malformations in infants: the importance of dosage. *Birth Defects Res B Dev*
33 *Reprod Toxicol* 2007;**80**(1):18-27.
34
35
36
37
38 15 (14) Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the
39 prevalence of congenital malformations. *Pharmacoepidemiol Drug Saf*
40 2007;**16**(10):1075-1085.
41
42
43
44
45
46 18 (15) Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in
47 pregnancy: a prospective, multicentre, controlled, observational study. *Br J Clin*
48 *Pharmacol* 2008;**66**(5):695-705.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 (16) Kallen BA, Otterblad OP. Maternal use of selective serotonin re-uptake inhibitors in
4
5 2 early pregnancy and infant congenital malformations. *Birth Defects Res A Clin Mol*
6
7 3 *Teratol* 2007;**79**(4):301-308.
8
9
10 4 (17) Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake
11
12 5 inhibitors in pregnancy and congenital malformations: population based cohort study.
13
14 6 *BMJ* 2009;**339**:b3569.
15
16
17 7 (18) Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in
18
19 8 pregnancy: an update using Swedish data. *Psychol Med* 2010 Oct;**40**(10):1723-33
20
21
22
23 9 (19) Wichman CL, Moore KM, Lang TR, et al. Congenital Heart Disease Associated With
24
25 10 Selective Serotonin Reuptake Inhibitor Use During Pregnancy. *Mayo Clinic*
26
27 11 *Proceedings* 2009;**84**(1):23-27.
28
29
30
31 12 (20) Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin
32
33 13 reuptake inhibitors and risk of congenital malformations. *Epidemiology*
34
35 14 2006;**17**(6):701-704.
36
37
38
39 15 (21) Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the
40
41 16 prevalence of congenital, specifically cardiac, defects: a meta-analysis of
42
43 17 epidemiological studies. *Birth Defects Res A Clin Mol Teratol* 2010;**88**(3):159-170.
44
45
46 18 (22) Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake
47
48 19 inhibitors in pregnancy. *Obstet Gynecol* 2005;**106**(6):1289-1296.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 (23) Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of
4 the new selective serotonin reuptake inhibitors: a prospective controlled multicenter
5 2 study. *JAMA* 1998;**279**(8):609-610.
6
7
8
9
10 4 (24) Ramos E, St-Andre M, Rey E, et al. Duration of antidepressant use during pregnancy
11 and risk of major congenital malformations. *The British Journal of Psychiatry*
12 2008;**192**(5):344-350.
13
14
15
16
17
18 7 (25) Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations in infants
19 following antidepressant exposure in pregnancy: results of a large prospective cohort
20 8 study. *Can J Psychiatry* 2009;**54**(4):242-246.
21
22
23
24
25
26 10 (26) Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations
27 and perinatal events among infants exposed to antidepressant medications during
28 11 pregnancy. *Pharmacoepidemiol Drug Saf* 2007;**16**(10):1086-1094.
29
30
31
32
33
34 13 (27) Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations
35 following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines
36 14 using population-based health data. *Birth Defects Res B Dev Reprod Toxicol*
37 15 2008;**83**(1):68-76.
38
39
40
41
42
43 17 (28) Simon GE, Cunningham ML, Davis RL. Outcomes of Prenatal Antidepressant
44 Exposure. *Am J Psychiatry* 2002;**159**(12):2055-2061.
45
46
47
48
49 19 (29) Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse
50 20 pregnancy outcomes. *Am J Obstet Gynecol* 2006;**194**(4):961-966.
51
52
53
54
55

- 1
2
3 1 (30) Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in
4
5 2 early pregnancy. *Eur J Clin Pharmacol* 1999;**55**(7):503-508.
6
7
8 3 (31) Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant
9
10 4 congenital heart defect. *Reproductive Toxicology* 2006;**21**(3):221-222.
11
12
13 5 (32) Lennestål RM, Kallen BM. Delivery Outcome in Relation to Maternal Use of Some
14
15 6 Recently Introduced Antidepressants. [Article]. *Journal of Clinical*
16
17 7 *Psychopharmacology* 2007;**27**(6):607-613.
18
19
20 8 (33) Pedersen CB, Gotzsche H, Møller JO, Mortensen PB. The Danish Civil Registration
21
22 9 System. A cohort of eight million persons. *Dan Med Bull* 2006;**53**(4):441-449.
23
24
25
26 10 (34) Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Dan Med Bull*
27
28 11 1998;**45**(3):320-323.
29
30
31 12 (35) Sørensen HT, Hansen I, Ejlersen E, et al. Identification of patients treated with strong
32
33 13 analgesics: an assessment of two Danish information systems with respect to
34
35 14 epidemiological research. *J Med Syst* 1996;**20**(1):57-65.
36
37
38
39 15 (36) Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. *Dan Med Bull*
40
41 16 1997;**44**(4):445-448.
42
43
44
45 17 (37) Statistics Denmark. Containing detailed statistical information on the Danish Society.
46
47 18 Available at: <http://www.dst.dk/en>. Accessed March, 2012.
48
49 19 (38) Andersen TF, Madsen M, Jørgensen J, et al. The Danish National Hospital Register.
50
51 20 A valuable source of data for modern health sciences. *Dan Med Bull* 1999;**46**(3):263-
52
53 21 268.
54
55

- 1
2
3 1 (39) European Surveillance of Congenital Anomalies. EUROCAT Guide 1.3 and reference
4 documents. Newtownabbey Co Antrim: University of Ulster; 2005. Available at:
5
6
7 3 <http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf>. Accessed March
8
9
10 4 2012.
- 11
12
13 5 (40) Fosbol EL, Gislason GH, Jacobsen S, et al. The pattern of use of non-steroidal anti-
14
15 inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million
16
17 7 people. *Pharmacoepidemiol Drug Saf* 2008;**17**(8):822-833.
- 18
19
20 8 (41) von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
21
22 Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting
23
24 9 observational studies. *Lancet* 2007;**370**(9596):1453-1457.
- 25
26
27
28 11 (42) Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin-reuptake
29
30 12 inhibitors during early pregnancy and risk of congenital malformations: updated
31
32 13 analysis. *Clin Epidemiol* 2010;**2**:29-36.
- 33
34
35
36 14 (43) Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations:
37
38 15 meta-Analysis and consideration of potential confounding factors. *Clin Ther*
39
40 16 2007;**29**(5):918-926.
- 41
42
43 17 (44) de Jong van den Berg LT, Feenstra N, Sorensen HT, et al.. Improvement of drug
44
45 18 exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and
46
47 19 mother as sources for drug exposure data during pregnancy. EuroMAP Group.
48
49 20 European Medicine and Pregnancy Group. *Teratology* 1999;**60**(1):33-36.
50
51
52
53
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 (45) Olesen C, Sondergaard C, Thrane N, et al. Do pregnant women report use of
2 dispensed medications? *Epidemiology* 2001;**12**(5):497-501.

For peer review only

Supplement A. Odds Ratios (OR) and 95% confidence intervals (95% CI) for the incidence and risk of congenital malformations among women exposed to individual SSRIs vs. women with no exposure

	SSRI (n=4183)		Citalopram (n=1606)		Escitalopram (n=293)		Fluoxetine (n=928)		Paroxetine (n=568)		Sertraline (n=817)	
	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a
Congenital malformations	208 (4.97)	1.33 (1.16-1.53)	89 (5.54)	89 (5.54-1.51)	8 (2.73)	0.69 (0.34-1.4)	41 (4.42)	1.18 (0.86-1.61)	26 (4.58)	1.25 (0.84-1.85)	44 (5.39)	1.41 (1.03-1.92)
Major	7 (0.17)	1.13 (0.54-2.39)	2 (0.12)	2 (0.12-0.84)	1 (0.34)	2.25 (0.32-16.05)	2 (0.22)	1.44 (0.36-5.79)	1 (0.18)	1.19 (0.17-8.45)	1 (0.12)	0.85 (0.12-6.07)
Of the nervous system	1 (0.02)	0.73 (0.1-5.21)	-	-	0 (0)	-	1 (0.11)	3.22 (0.45-23.03)	0 (0)	-	0 (0)	-
Neural Tube Defects	7 (0.17)	1.43 (0.68-3.01)	5 (0.31)	5 (0.31-2.62)	0 (0)	-	1 (0.11)	0.93 (0.13-6.63)	0 (0)	-	1 (0.12)	1.05 (0.15-7.45)
Of the eye	2 (0.05)	2.36 (0.58-9.61)	0 (0)	-	0 (0)	-	0 (0)	-	1 (0.18)	8.32 (1.16-59.81)	1 (0.12)	6.13 (0.85-44.05)
Of the ear, face and neck	77 (1.84)	2.01 (1.6-2.53)	28 (1.74)	28 (1.74-1.91)	3 (1.02)	1.06 (0.34-3.3)	17 (1.83)	2.05 (1.27-3.31)	8 (1.41)	1.54 (0.77-3.1)	21 (2.57)	2.73 (1.75-4.26)
Of the heart	49 (1.17)	2.04 (1.53-2.72)	17 (1.06)	17 (1.06-1.86)	2 (0.68)	1.12 (0.28-4.51)	9 (0.97)	1.73 (0.89-3.33)	6 (1.06)	1.89 (0.85-4.23)	15 (1.84)	3.09 (1.82-5.25)
Septal defects	21 (0.5)	1.62 (1.05-2.5)	7 (0.44)	7 (0.44-1.41)	0 (0)	0 (0-0)	3 (0.32)	1.03 (0.33-3.2)	2 (0.35)	1.13 (0.28-4.54)	9 (1.1)	3.6 (1.86-6.96)
Ventricular septal defects	34 (0.81)	2.6 (1.84-3.68)	12 (0.75)	12 (0.75-2.41)	1 (0.34)	1.01 (0.14-7.23)	7 (0.75)	2.53 (1.2-5.32)	6 (1.06)	3.51 (1.57-7.87)	8 (0.98)	2.85 (1.35-5.99)
Atrial septal defects	2 (0.05)	1.25 (0.31-5.02)	0 (0)	-	1 (0.34)	8.71 (1.21-62.64)	0 (0)	-	0 (0)	-	1 (0.12)	3.22 (0.45-23.03)
Atrioventricular septal	7 (0.17)	1.41 (0.67-2.98)	2 (0.12)	2 (0.12-1.03)	1 (0.34)	2.66 (0.37-19.02)	1 (0.11)	0.94 (0.13-6.67)	1 (0.18)	1.52 (0.21-10.8)	2 (0.24)	2.09 (0.52-8.38)
Of the respiratory system	6 (0.14)	1.02 (0.46-2.27)	4 (0.25)	4 (0.25-1.8)	0 (0)	-	1 (0.11)	0.76 (0.11-5.4)	0 (0)	0 (0-0)	1 (0.12)	0.88 (0.12-6.24)
Oro-facial clefts	13 (0.31)	1.8 (1.04-3.12)	7 (0.44)	7 (0.44-2.5)	0 (0)	-	2 (0.22)	1.25 (0.31-5)	2 (0.35)	2.09 (0.52-8.39)	2 (0.24)	1.43 (0.36-5.74)
Of the digestive system	1 (0.02)	1.04 (0.14-7.44)	1 (0.06)	1 (0.06-2.54)	0 (0)	-	0 (0)	-	0 (0)	-	0 (0)	-
Abdominal wall defects	11 (0.26)	0.84 (0.45-1.57)	9 (0.56)	9 (0.56-2.02)	0 (0)	-	0 (0)	-	0 (0)	-	2 (0.24)	0.44 (0.06-3.11)
Of the internal urinary system	19 (0.45)	1.55 (0.99-2.44)	8 (0.5)	8 (0.5-1.7)	1 (0.34)	1.08 (0.15-7.67)	3 (0.32)	1.09 (0.35-3.38)	6 (1.06)	3.83 (1.71-8.57)	1 (0.12)	0.41 (0.06-2.93)
Of the external genital organs	53 (1.27)	0.93 (0.71-1.23)	24 (1.49)	24 (1.49-1.13)	1 (0.34)	0.25 (0.04-1.75)	10 (1.08)	0.76 (0.41-1.42)	7 (1.23)	0.91 (0.43-1.92)	11 (1.35)	1 (0.55-1.81)
Of the limbs	8 (0.19)	1.29 (0.64-2.59)	3 (0.19)	3 (0.19-1.25)	1 (0.34)	2.18 (0.31-15.57)	2 (0.22)	1.46 (0.36-5.85)	1 (0.18)	1.2 (0.17-8.55)	1 (0.12)	0.83 (0.12-5.9)
Of the musculoskeletal system	7 (0.17)	1.57 (0.74-3.31)	1 (0.06)	1 (0.06-0.59)	0 (0)	-	1 (0.11)	0.97 (0.14-6.92)	3 (0.53)	4.65 (1.49-14.53)	2 (0.24)	2.35 (0.59-9.45)
Chromosomal abnormalities												

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	9	1.36	4	4	0	-	4	3.08	0	-	1	0.88
Other malformations	(0.22)	(0.68-2.74)	(0.25)	(0.25-1.32)	(0)	-	(0.43)	(1.15-8.23)	(0)	-	(0.12)	(0.12-6.28)
	2	2.78	1	1	0	-	0	-	0	-	1	10.13
And teratogenic syndromes	(0.05)	(0.67-11.6)	(0.06)	(0.06-3.58)	(0)	-	(0)	-	(0)	-	(0.12)	(1.36-75.44)
	1	0.39	0	-	0	-	1	1.79	0	-	0	-
Genetic syndromes	(0.02)	(0.06-2.78)	(0)	-	(0)	-	(0.11)	(0.25-12.76)	(0)	-	(0)	-

Incidence is presented as number of cases (N) with percentages (%). Estimates of multivariable logistic regressions are presented as Odds Ratios (OR) with 95% confidence intervals (95% CI) ^aMultivariable logistic regressions are adjusted for mother’s age, parity, income, education, smoking and year of conception.



Supplement B. Risk of congenital malformations among women exposed to an SSRI vs. women with no exposure further adjusted for co-medication.

Outcome	Exposed to any SSRI				No exposure
	First trimester N=4183		Paused during pregnancy N=806		N=843 797
	N (%)	OR (96% CI)	N (%)	OR (96% CI)	N (%)
Major malformations	208 (4.97)	1.32 (1.14-1.52)	36 (4.47)	1.27 (0.91-1.77)	29703 (3.52)
Congenital malformations of the heart	77 (1.84)	1.98 (1.57-2.49)	13 (1.61)	1.84 (1.06-3.19)	7755 (0.92)
Septal defects	49 (1.17)	2.00 (1.50-2.67)	11 (1.36)	2.54 (1.40-4.62)	4826 (0.57)
Ventricular septal defects	21 (0.50)	1.58 (1.02-2.44)	9 (1.12)	3.71 (1.92-7.17)	2803 (0.33)
Atrial septal defects	34 (0.81)	2.54 (1.79-3.60)	6 (0.74)	2.60 (1.16-5.81)	2490 (0.30)
Congenital malformations of the digestive system	13 (0.31)	1.74 (1.00-3.02)	1 (0.12)	0.74 (0.10-5.29)	1545 (0.18)
Congenital malformations of the internal urinary system	11 (0.26)	0.86 (0.46-1.60)	-	-	2333 (0.28)
Congenital malformations of the external genital organs	19 (0.45)	1.53 (0.97-2.41)	2 (0.25)	0.89 (0.22-3.57)	2504 (0.30)
Congenital malformations of the limbs	53 (1.27)	0.93 (0.71-1.22)	14 (1.74)	1.36 (0.80-2.31)	11785 (1.40)

Estimates are presented as Odds Ratios (OR) with 95% confidence intervals (95% CI). Multivariable logistic regressions are adjusted for mother's age, parity, income, education, smoking, year of conception and co-medication with psycholeptics and antidiabetics.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	7,8
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9,10
		(b) Indicate number of participants with missing data for each variable of interest	8
		(c) Summarise follow-up time (eg, average and total amount)	-
Outcome data	15*	Report numbers of outcome events or summary measures over time	9,10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-16
		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	13
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14-16
Discussion			
Key results	18	Summarise key results with reference to study objectives	16,17
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16-21
Generalisability	21	Discuss the generalisability (external validity) of the study results	21
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nation-wide cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001148.R2
Article Type:	Research
Date Submitted by the Author:	09-May-2012
Complete List of Authors:	Jimenez-Solem, Espen; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Andersen, Jon Traerup; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Petersen, Morten; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Brødbæk, Kasper; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Afzal, Shoaib; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Jensen, Jonas; Gentofte Hospital, Department of Cardiology Gislason, Gunnar; Copenhagen University Hospital Gentofte, Department of Cardiology Torp-Pedersen, Christian; University of Copenhagen, Faculty of Health Sciences; Gentofte Hospital, Department of Cardiology Poulsen, Henrik; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology
Primary Subject Heading:	Pharmacology and therapeutics
Secondary Subject Heading:	Epidemiology, Mental health, Reproductive medicine, obstetrics and gynaecology
Keywords:	CLINICAL PHARMACOLOGY, EPIDEMIOLOGY, Fetal medicine < OBSTETRICS, Maternal medicine < OBSTETRICS, Depression & mood disorders < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **EXPOSURE TO SELECTIVE SEROTONINE REUPTAKE INHIBITORS AND THE RISK**
2 **OF CONGENITAL MALFORMATIONS: A NATION-WIDE COHORT-STUDY**

3
4 Espen Jimenez-Solem, M.D.1,2, Jon Trærup Andersen, M.D.1,2, Morten Petersen, M.D.1,2, Kasper
5 Broedbaek, M.D.1,2, Jonas Krogh Jensen, M.B. 3, Shoaib Afzal, M.D.1,2, Gunnar Gislason, M.D.
6 3, Christian Torp-Pedersen D.M.Sc.3,4, Henrik Enghusen Poulsen, D.M.Sc.1,2,4

7
8 1 Laboratory of Clinical Pharmacology Q7642, Rigshospitalet, Copenhagen, Denmark

9 2 Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark

10 3 Department of Cardiology, Gentofte Hospital, Denmark

11 4 Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

12

13 **Correspondence:**

14 M.D. Espen Jimenez-Solem, Laboratory of Clinical Pharmacology Q7642, Rigshospitalet,

15 Tagensevej 20, DK-2200 Copenhagen, Denmark

16 **E-mail:** espen.jimenez.solem@rh.regionh.dk

17 **Phone:** +45 3545 7642

18 **Fax:** +45 3545 2745

19 **Key words:** Pregnancy, antidepressive agents, serotonin uptake inhibitors, congenital

20 malformations, pharmacoepidemiology.

21 **Word count (main text):** 33873266

22

1
2
3
4 **1 ABSTRACT**

5
6
7 **2 Objectives**

8
9 To analyse the relation between selective serotonin reuptake inhibitor (SSRI) use and major
10 congenital malformations, with focus on malformations of the heart.
11
12

13
14 **5 Design**

15
16 Register based retrospective nation-wide cohort study, using the Danish Medical Birth Registry.
17
18

19
20 **7 Setting**

21
22 Denmark
23
24

25
26 **9 Participants**

27
28 Pregnant women in Denmark between 1997 and 2009 and their offspring.
29

30
31 **11 Primary outcome measures**

32
33 For each SSRI odds ratios for major congenital malformations were estimated using multivariable
34 logistic regression models for women exposed to an SSRI during the first trimester and for women
35 with paused exposure during pregnancy.
36
37
38

39
40 **15 Results**

41
42
43 We identified 848 786 pregnancies; 4183 were exposed to an SSRI throughout the first trimester,
44 and 806 pregnancies paused exposure during pregnancy. Risks of congenital malformations of the
45 heart were similar for pregnancies exposed to an SSRI throughout the first trimester; adjusted OR
46 2.01 (95% CI 1.60-2.53) and for pregnancies with paused SSRI treatment during pregnancy;
47
48
49
50
51
52
53
54
55
56
57
58
59
60
adjusted OR 1.85 (95% CI 1.07-3.20). P-value for difference: 0.94. We found similar increased

1
2
3
4 1 risks of specific congenital malformations of the heart for the individual SSRIs. Furthermore, we
5
6 2 found no association with dosage.
7
8

9
10 3 **Conclusions**

11
12 4 The apparent association between SSRI use and congenital malformations of the heart may be
13
14 5 confounded by indications. The moderate absolute risk increase combined with uncertainty for
15
16 6 causality still requires the risk versus benefit to be evaluated in each individual case.
17
18
19 7

1
2
3
4 **1 ARTICLE SUMMARY**
5
6

7 **2 Article focus**
8

- 9
10 • Relation between SSRIs and congenital malformations
11
12 • Focus on malformations of the heart
13
14 • Focus on women with paused treatment during pregnancy
15

16
17 **6 Key messages**
18

- 19
20 • Risks of congenital malformations of the heart are increased for infants whose mothers were
21 exposed to an SSRI during the first trimester.
22
23 • Risks of congenital malformations of the heart are not different for pregnancies exposed
24 during the first trimester as for pregnancies with paused treatment during pregnancy.
25
26
27
28 • The found risk increases are moderate in absolute terms.
29
30

31 **12 Strengths and limitations of this study**
32

- 33 • Observational study – no causal relations.
34
35 • Nation-wide study, including all live births in the study period.
36
37 • Register based study - no recall bias.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

ARTICLE

Introduction

Depression is common during pregnancy and up to 15% of pregnant women suffer from depression or depressive symptoms.^{1;2} The most used pharmacological treatment for pregnant women is selective serotonin reuptake inhibitors (SSRIs).³⁻⁶ Treatment with SSRIs during pregnancy in Denmark has doubled over a short span of time with 1.4% of pregnancies treated in 2004 compared to 2.4% in 2007. This rapid increase has also been observed in other countries where the proportion of pregnant women treated with an SSRI is reported to be even higher than in Denmark.⁴⁻⁸ Several studies have analysed the consequences of this treatment on pregnancy outcomes, and indicated an increased risk of congenital malformations^{9;10}, and more notably heart defects.¹¹⁻²¹ However, the data are conflicting^{11;13;16-18;22-32} and studies including up to a million pregnancies indicate little risk of congenital malformations^{11,16;18;30;31}. None of these studies have successfully managed to differentiate between the consequences of the drugs themselves and the underlying disease. Given the uncertainty of safety and the common use, we performed a nationwide study of the relation between SSRI use and congenital malformations with focus on congenital heart defects, and comparison with paused use during pregnancy to account for special characteristics of women using antidepressants.

Materials and methods

Through the Danish Medical Birth Registry we identified all pregnancies in Denmark between 1997 and 2009. Their drug redemptions were identified using the Register of Medicinal Product Statistics. We calculated the associations between exposure to SSRIs and congenital malformations using multivariable logistic regression adjusted for maternal characteristics.

1 Study Population

2 At birth, all Danish citizens are given a unique permanent identification number³³,
3 which enables personalized information to be linked across databases.. Using The Danish Medical
4 Birth Registry we identified 854,008 births between 1997 and 2009. We excluded 5,222 records
5 with missing data on date of birth and pregnancy length. The final cohort consisted of 848,786
6 pregnancies (99.4 % of all pregnancies). The Danish Medical Birth Registry includes data on all
7 births in Denmark since 1973³⁴ and the following information is contained: unique identification
8 numbers of mother and child as well recorded time of gestation, which is based on last menstrual
9 period and ultrasound estimates. We obtained medical treatment from the Danish Register of
10 Medicinal Product Statistics, which, since 1995, has recorded drugs dispensed from Danish
11 pharmacies. Registration is close to perfect due to partial reimbursement by health-care authorities.
12 ³⁵ For this reason, direct importing by patients is nearly non-existent. The register contains type of
13 drug (International Anatomical Therapeutic Coding (ATC)), date of redemption, quantity dispensed
14 and strength.³⁶ Information on smoking was gathered from the Danish Medical Birth Registry.
15 Individual information on household income and highest attained level of education was gathered
16 from Statistics Denmark.³⁷

17 Outcome Measures

18 Congenital malformations were identified through the Danish National Hospital
19 Register.³⁸ We identified children with congenital malformation within one year of birth and the
20 corresponding grouping according to the European Surveillance of Congenital Anomalies
21 (EUROCAT) classification system guide 1.3.³⁹

1
2
3
4 1 Identification of Exposure

5
6 2 Exposure to the following SSRIs (ATC codes) was identified in the present study:
7
8 3 fluoxetine (N06AB03), citalopram (N06AB04), paroxetine (N06AB05), sertraline (N06AB06), and
9
10 4 escitalopram (N06AB10). Other SSRIs were not included because of low incidence of use (n<50).
11
12

13
14 5 SSRI prescriptions redeemed during the study period were identified through the
15
16 6 Register of Medicinal Product Statistics. Using the date of prescription, strength and number of
17
18 7 tablets prescribed we performed an estimation of exposure periods and dosages of the individual
19
20 8 SSRIs. We calculated dosage as the average of up to seven prescriptions based on the standard dose
21
22 9 of the individual antidepressant. Calculation of drug exposure periods using this method has been
23
24 10 described previously.⁴⁰
25
26
27

28 11 We identified all pregnancies exposed to an SSRI during the first trimester with a
29
30 12 continuous exposure before pregnancy by defining it as exposure between at least one month before
31
32 13 conception and day 84 of pregnancy (last day of the first trimester). Women changing exposure to
33
34 14 another SSRI during the first trimester were not included in the study (n=646). In order to address a
35
36 15 possible confounding by indication we compared our cohort exposed during the first trimester with
37
38 16 a control cohort comprised of women with paused exposure during pregnancy. We defined women
39
40 17 with paused exposure as exposure to an SSRI three to twelve months before conception and one to
41
42 18 twelve months after giving birth, but with no exposure to an SSRI between three months before
43
44 19 conception to one month after giving birth. In addition, they had to be exposed to the same
45
46 20 individual SSRI before and after pregnancy to ensure comparability with women exposed during
47
48 21 the first trimester.
49
50
51
52
53
54
55

1 We divided the study population into pregnancies exposed to high or low SSRI dose
2 based on the recommended daily dose values of the individual SSRIs during pregnancy. Doses over
3 the following cut-off values were considered as high doses; 20 mg for citalopram, 10 mg for
4 escitalopram, 20 mg for fluoxetine, 20 mg for paroxetine and 50 mg for sertraline.

5 Statistical Analysis

6 Baseline characteristics were compared with chi-square tests for categorical variables. Risks of
7 malformations were examined with linear logistic regression models. In multivariable analyses we
8 included the mother's age divided into 5 categories: <20, 20-25, 25-30, 30-35, >35 years (0%
9 missing values). Annual gross household income was divided into quartiles (<1% missing values).
10 The highest obtained level of education attained was divided into three groups: low, medium and
11 high, resulting in 4.3% missing values. The number of prior births (parity), including stillbirths, was
12 divided into four classes: 1, 2, 3 and >3 births (<1% missing values). Year of conception was
13 divided into 5 categories (1995-97, 1998-2000, 2001-03, 2004-06, and 2007-09). Smoking was
14 divided into five categories according to the number of daily cigarette: 0, 1-10, 11-20, >20 and
15 unknown (<1% missing values). Body mass index (BMI) was divided into 5 group (<21, 21-25, 26-
16 30, >30). Information on BMI was only available from January 1st 2004, and includes 7% missing
17 values in the period 2004-2009. (Table 1) Records with missing values in the above mentioned
18 categories were not included in the multivariable analyses.

19 Ethics

20 The present study has been approved by The Danish Data Protection Agency (No.
21 2008-41-2517). Retrospective register studies do not require ethical permission in Denmark. Our
22 findings are reported according to strengthening the reporting of observational studies in
23 epidemiology (STROBE).⁴¹

1 Results

2 We identified 4183 pregnancies exposed to an SSRI throughout the first trimester, 806
 3 pregnancies with paused exposure, and 843 797 pregnancies not exposed to an SSRI. 83% of
 4 pregnancies exposed to an SSRI throughout the first trimester went on to redeem a prescription of
 5 an SSRI during the third trimester. Table 1 shows the basic characteristics for women exposed and
 6 to an SSRI, and for unexposed women. Table 2 presents the association between exposure to SSRIs
 7 and major congenital malformation with more than 10 cases, and specific septal congenital defects
 8 of the heart. For information on risks associated with the remaining congenital malformations
 9 please refer to supplement A.

10 **Table 1. Maternal characteristics of women exposed to an SSRI and unexposed**

Characteristic	Exposed to SSRIs		Unexposed	
	First trimester N=4 183 N (%)	Paused during pregnancy N=806 N (%)	p-value ^a	N=843 797 N (%) p-value ^a
Education			<0.01	<0.001
short	1731 (41.38)	372 (46.15)		280447 (33.24)
medium	1119 (26.75)	225 (27.92)		254194 (30.13)
long	1262 (30.17)	193 (23.95)		272380 (32.28)
Missing values	71 (1.70)	16 (1.99)		36776 (4.36)
Annual household income			0.12	<0.001
less than \$ 58 335	1320 (31.56)	264 (32.75)		210290 (24.92)
\$ 58 335 - \$ 93 656	1101 (26.32)	222 (27.54)		212110 (25.14)
\$ 93 656 - \$ 119 082	906 (21.66)	185 (22.95)		211436 (25.06)
\$ 119 082 or greater	856 (20.46)	135 (16.75)		207247 (24.56)
Missing values	0 (-)	0 (-)		2714 (0.32)
Age (years)			<0.001	<0.001
<20	70 (1.67)	20 (2.48)		23324 (2.76)
21-25	555 (13.27)	122 (15.14)		129059 (15.30)
26-30	1364 (32.61)	269 (33.37)		318664 (37.77)
31-35	1423 (34.02)	295 (36.60)		268959 (31.87)
>35	771 (18.43)	100 (12.41)		102791 (12.18)

Missing values	0 (-)	0 (-)		0 (-)
Parity			<0.001	<0.001
1	1983 (47.41)	282 (34.99)		368168 (43.63)
2	1320 (31.56)	310 (38.46)		308992 (36.62)
>2	833 (19.91)	208 (25.81)		162030 (19.20)
Missing values	47 (1.12)	6 (0.74)		4607 (0.55)
Daily cigarettes			0.53	<0.001
0	2810 (67.18)	532 (66)		660888 (78.32)
1-10	1049 (25.08)	211 (26.18)		128269 (15.2)
11-20	66 (1.58)	11 (1.36)		5294 (0.63)
>20	138 (3.30)	34 (4.22)		20967 (2.48)
No information	118 (2.82)	18 (2.23)		27580 (3.27)
Missing values	2 (0.05)	0 (-)		799 (0.09)
Pre-pregnancy BMI^b			0.89	<0.001
<21	391 (12.23)	66 (12.60)		53500 (13.95)
21-25	1393 (43.59)	233 (44.47)		186428 (48.62)
26-30	705 (22.06)	117 (22.33)		74673 (19.48)
>30	493 (15.43)	74 (14.12)		41652 (10.86)
Missing values	214 (6.70)	35 (6.68)		27161 (7.08)

Data indicate number of pregnancies (N) and percentage (%). ^aChi square tests were used to assess the overall p value for the group comparison with pregnancies exposed to an SSRI during the first trimester. ^bBMI=body mass index. Information on pre-pregnancy BMI was only available for women giving birth after 1. January 2004. Thus this cohort comprises 387 142 pregnancies

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

1

Table 2. Risk of congenital malformations among women exposed to an SSRI vs. women with no exposure

Outcome	Exposed to any SSRI				p-value ^a	No exposure N=843 797 N (%)
	First trimester N=4183		Paused during pregnancy N=806			
	N (%)	OR (95% CI)	N (%)	OR (95% CI)		
Major malformations	208 (4.97)	1.33 (1.16-1.53)	36 (4.47)	1.27 (0.91-1.78)	0.90	29703 (3.52)
Congenital malformations of the heart	77 (1.84)	2.01 (1.60-2.53)	13 (1.61)	1.85 (1.07-3.20)	0.94	7755 (0.92)
Septal defects	49 (1.17)	2.04 (1.53-2.72)	11 (1.36)	2.56 (1.41-4.64)	0.35	4826 (0.57)
Ventricular septal defects	21 (0.50)	1.62 (1.05-2.50)	9 (1.12)	3.74 (1.93-7.23)	0.97	2803 (0.33)
Atrial septal defects	34 (0.81)	2.60 (1.84-3.68)	6 (0.74)	2.61 (1.17-5.84)	0.74	2490 (0.30)
Congenital malformations of the digestive system	13 (0.31)	1.80 (1.04-3.12)	1 (0.12)	0.75 (0.11-5.35)	0.59	1545 (0.18)
Congenital malformations of the internal urinary system	11 (0.26)	0.84 (0.45-1.57)	-	-	-	2333 (0.28)
Congenital malformations of the external genital organs	19 (0.45)	1.55 (0.99-2.44)	2 (0.25)	0.89 (0.22-3.59)	0.46	2504 (0.30)
Congenital malformations of the limbs	53 (1.27)	0.93 (0.71-1.23)	14 (1.74)	1.37 (0.80-2.32)	0.18	11785 (1.40)

Estimates are presented as Odds Ratios (OR) with 95% confidence intervals (95% CI) ^aP-value for comparison of odds ratios between pregnancies exposed throughout the first trimester and pregnancies with paused exposure during pregnancy. ^bMultivariable logistic regressions are adjusted for mother’s age, parity, income, education, smoking and year of conception.

1 First trimester exposure to any SSRI vs. no exposure

2 The rate of major congenital malformations among pregnancies exposed to any
3 SSRI throughout the first trimester was 50 per 1000 pregnancies, compared to 35 pr 1000
4 unexposed pregnancies (Figure 1). We found an association between SSRI exposure and
5 major congenital malformations; adjusted OR=1.33 (95% CI, 1.16-1.53) (table 2).

6 When analysing the association between exposure to any SSRI and the different
7 major malformations according to the EUROCAT classification we found a statistically
8 significant association between exposure to an SSRI and congenital malformations of the
9 heart; adjusted OR=2.01 (95% CI, 1.60-2.53), and congenital malformations of the digestive
10 system; adjusted OR=1.80 (95% CI, 1.04-3.12), but not the remaining major congenital
11 malformations (table 2).

12 Paused exposure vs. unexposed

13 The rate of major congenital malformations among pregnancies with paused
14 exposure during pregnancy was 45 per 1000 pregnancies (Figure 1). The risk of any major
15 malformation for women with paused exposure to an SSRI during pregnancy was; adjusted
16 OR=1.27 (95% CI, 0.91-1.78) compared to unexposed pregnancies. When estimating the risk
17 of specific major congenital malformations we found that paused exposure was associated
18 with congenital malformations of the heart; adjusted OR 1.85 (95% CI, 1.07-3.20) (table 2).

19 We performed additional analyses increasing the drug-free period before pregnancy to six
20 and nine months and found similar estimates as for the group pausing exposure three months
21 before conception (supplement C).

Figure 1. Rates per 1000 pregnancies of major congenital malformations for infants exposed to selective serotonin reuptake inhibitors in utero




Figure shows number of infants diagnosed with a major malformation per 1000 births. Rates are shown with 95 % confidence intervals.

1
2
3 1 Other Analyses
4

5
6 2 *Exposure to individual SSRIs*
7

8 We found a significant association between major congenital malformations
9 and exposure to citalopram; adjusted OR=1.51 (95% CI, 1.21-1.87), and sertraline; adjusted
10 OR=1.41 (95% CI, 1.03-1.92). Furthermore, we found an association between congenital
11 malformations of the heart and exposure to citalopram; adjusted OR=1.91 (95% CI, 1.31-
12 2.77), fluoxetine; adjusted OR=2.05 (95% CI, 1.27-3.31), and sertraline; adjusted OR=2.73
13 (95% CI, 1.75-4.26). Associations for the remaining major congenital malformations are
14 presented in supplement A.
15
16
17
18
19
20
21
22
23

24 10 *Specific heart defects*
25

26 We performed a sub analysis of the specific congenital septal defects of the
27 heart and their association with exposure to SSRIs and found an association between
28 exposure to any SSRI and septal heart defects; adjusted OR=2.04 (95% CI, 1.53-2.72) (table
29 2). Specifically, ventricular septal defects and atrial septal defects were associated with an
30 increased risk. Increased risk of congenital septal defects was also found for pregnancies with
31 paused exposure; adjusted OR=2.56 (95% CI, 1.41-4.64) (table 2).
32
33
34
35
36
37
38
39

40 For the individual SSRIs we found an association between exposure to all
41 SSRIs, except for escitalopram, and atrial septal defects. Ventricular septal defects was only
42 associated with exposure to sertraline; adjusted OR=3.60 (95% CI, 1.86-6.96), and not the
43 remaining individual SSRIs (supplement A).
44
45
46
47
48
49
50
51
52
53
54
55

1
2
3 1 *Other congenital defects*

4
5 2 Studies have reported a possible association between exposure to an SSRI
6
7 3 during pregnancy and omphalocele, anencephaly and craniosynostosis.^{9:10} We found an
8
9 4 association for exposure to an SSRI in the first trimester and craniosynostosis (n=9); adjusted
10
11 5 OR=1.94 (95% CI, 1.00-3.76), but not for omphalocele or anencephaly. For pregnancies with
12
13 6 paused exposure, the association with craniosynostosis (n=3) was; adjusted OR=3.64 (95%
14
15 7 CI, 1.17-11.34).

16
17
18
19 8 *Dosage*

20
21 9 We found an adjusted odds ratio for major malformations: OR 1.39 (95% CI,
22
23 10 1.14-1.68) for low dose exposure and 1.27 (95% CI, 1.03-1.56) for high dose exposure (p for
24
25 11 difference=0.29).

26
27
28
29 12 For the individual major malformations we found similar associations for
30
31 13 pregnancies exposed to low dose and pregnancies exposed to high dose, as for the whole
32
33 14 cohort (Table 3). Analysing the effect of dose as a continuous variable yielded no dose-
34
35 15 response association.

36
37
38
39 **Table 3. Odds Ratios (OR) and 95% confidence intervals (95% CI) for association between congenital**
40 **malformations among women exposed to low and high doses SSRI during pregnancy.**

Outcome	Low dose SSRI (n=2588)		High dose SSRI (n=1603)		p-value ^b
	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	
Major malformations	121 (4.68)	1.26 (1.05-1.51)	87 (5.43)	1.44 (1.15-1.79)	0.29
Congenital malformations of the heart	44 (1.70)	1.83 (1.35-2.48)	33 (2.06)	2.26 (1.60-3.19)	0.41
Congenital malformations of the digestive system	8 (0.31)	1.78 (0.89-3.58)	5 (0.31)	1.80 (0.75-4.35)	0.99
Congenital malformations of the internal urinary system	6 (0.23)	0.82 (0.37-1.83)	5 (0.31)	0.88 (0.33-2.34)	0.63
Congenital malformations of the external genital organs	10 (0.39)	1.32 (0.71-2.46)	9 (0.56)	1.91 (0.99-3.68)	0.42

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Congenital malformations of the limbs**

33 (1.28) 0.94 (0.67-1.33) 20 (1.25) 0.91 (0.59-1.42) 0.93

^aMultivariable logistic regressions are adjusted for mother's age, parity, income, education, smoking and year of conception. ^bP-value for comparison of odds ratios between pregnancies exposed to low dose SSRI and high dose SSRI.

3

4 *Additional adjustments*

5 In order to identify possible unaccounted confounders we performed additional
6 multivariable analyses including co-medication (psycholeptics; ATC code A05, and
7 antidiabetics; ATC code A10) as independent variables in our model. The results showed no
8 considerable change in the estimates or their level of significance compared to our primary
9 analysis (Supplement B).

10 When including body mass index (BMI) as an independent variable in our
11 multivariable model we found the same statistically significant associations for exposure to
12 any SSRI or individual SSRIs, and the specific congenital malformations as our multivariable
13 model not adjusted for BMI. Information on BMI was only available for pregnancies after
14 January 1st 2004, which reduced our cohort to 3196 pregnancies exposed to an SSRI and 383
15 946 with no exposure.

16 *Non-SSRI antidepressants*

17 The association between congenital malformations and exposure to non-SSRI
18 antidepressants: tricyclic antidepressants (ATC N06AA, n=223) and other antidepressants
19 (ATC N06AX, n=831) was; adjusted OR=1.04 (95% CI, 0.53-2.03) and; adjusted OR=0.70
20 (95% CI, 0.47-1.05), respectively. The associations with congenital malformations of the
21 heart were; adjusted OR=1.33 (95% CI, 0.42-4.15) for tricyclic antidepressants and adjusted
22 OR=0.99 (95% CI 0.51-1.91) for other antidepressants.

1 Discussion

2 We performed a retrospective nation-wide cohort study analysing the
3 association between redemption of an SSRI during pregnancy and major congenital
4 malformations. We found an association between exposure to an SSRI during the first
5 trimester and major congenital malformations. More specifically; congenital malformations
6 of the heart (ventricular septal defects and atrial septal defects) and congenital malformations
7 of the digestive system. Furthermore, we found an association between women with paused
8 SSRI exposure during pregnancy and congenital malformations of the heart. Based on
9 findings described in the published literature we will centre the following discussion on
10 major congenital malformations and congenital malformations of the heart for pregnancies
11 exposed to SSRIs.

12 Our study's results are in accordance with two earlier Danish studies^{20;42} based
13 on cohorts comprising only part of the entire nation. A third Danish nation-wide study by
14 Pedersen et al found an increased estimate for major congenital malformations and congenital
15 malformations of the heart, though not statistically significant, in the studied period 1996-
16 2004.¹⁷ The number of exposed women in their study was 1370, compared to ours 4183,
17 which could explain why our estimates reached statistical significance. The study concludes
18 that there is a class effect of SSRIs on heart defects.

19 Several studies have not found an association between exposure to any SSRI
20 and major malformations overall.^{11;13;16;18;22-32} We find that some of these study are not
21 comparable to ours because most of them are case-control studies, and with cohorts much
22 smaller than ours.^{13;22-29;31} Five of the studies are though similar to ours; based on nation-

1 wide cohorts and national registers, and cohort-sizes comparable to ours. Four are based on
2 Swedish data and are successive updates^{16;18;30;31}, and one on Finnish data.¹¹

3 The latest update of Swedish data found an increased risk of cardiovascular
4 congenital malformations for pregnancies exposed to paroxetine, but not for the remaining
5 individual SSRIs, or SSRI as a group.¹⁸ Information on SSRI exposure was partly based on
6 antenatal interviews which could, although unlikely, give rise to recall bias. Furthermore,
7 their analyses were adjusted for BMI. Adjusting our multivariable analysis for BMI had little
8 effect the estimates.

9 The Finnish study found an increased risk of ventricular septal defects for
10 pregnancies exposed to fluoxetine, but not for the remaining individual SSRIs, or SSRI as a
11 group.¹¹ The study is completely based on national registers, like our study. Exposure was
12 though defined as redemption of at least one prescription between one month before
13 pregnancy and the end of the first trimester. This could underestimate the number of exposed
14 women if prescriptions for an SSRI were redeemed just before and after this chosen period.
15 This could indicate continuous exposure during the first trimester and push estimates
16 towards unity, and, in theory, explain the lack of association with major congenital
17 malformations, and specifically atrial septal defects.

18 None of the above mentioned studies assessed the risk of congenital
19 malformations for women with paused exposure during pregnancy and thereby addressing the
20 possibility of confounding by indication. Furthermore, neither the Swedish nor the Finnish
21 studies adjusted their analyses for socioeconomic factors which in our study are unevenly
22 distributed between our exposed and unexposed population. However, additional adjusted
23 analyses not including socioeconomic factors yielded estimates and confidence intervals that

1 | did not differ from our fully adjusted analysis (data not shown). Importantly, we believe
2 | there are sociodemographic differences between the populations included in these
3 | Scandinavian studies compared to ours. Although Denmark resembles both Sweden and
4 | Finland, differences in culture and health care policies could account for the discrepancies in
5 | our results. Discrepancies between published studies could also be due to the low number of
6 | cases, where each case can have a significant effect on the estimate.

7 | Congenital malformations of the heart have been associated with exposure to
8 | SSRIs in some studies^{10-12;15-18;27;31;42}, in contrast to studies not identifying this
9 | association.^{9;13;19;26} Our analyses showed an increased risk of congenital heart defects for the
10 | individual SSRIs. Risks of atrial septal defects were furthermore associated with exposure to
11 | all individual SSRIs, except for escitalopram. The lack of statistical significance with
12 | escitalopram exposure could be due to low statistical power. We found the same increased
13 | risks for heart defects for those with paused exposure during pregnancy, which strengthens
14 | the assumption of confounding by indication.

15 | Although statistically significant, the increased risks associated with SSRI
16 | exposure are small in absolute terms. For example, the populations' background risk of atrial
17 | septal defects is 0.26 %, and even if we estimate a two-fold risk increase associated with
18 | exposure to any SSRI the risk of giving birth to a child with this congenital malformation
19 | would be approximately 5 cases for every 1000 births (Figure 1).

20 | Strengths and limitations

21 | The main weakness is the observational design. We had access to important
22 | covariates but it cannot be excluded that unaccounted confounder explain the results. Our
23 | study could furthermore be affected by a possible detection bias. Pregnant women exposed to

1
2
3 1 SSRIs are reported to have increased rates of observed malformations, due to increased rates
4
5 2 of ultrasound examinations compared to women not treated with SSRIs.⁴³ In contrast,
6
7 3 detection of a malformation during an ultrasound examination could lead to pregnancy
8
9 4 termination, and thereby decreased rates of malformations among the SSRI exposed. On the
10
11 5 other hand, infants of women redeeming prescriptions for SSRIs undergo, in the first year of
12
13 6 life, approximately twice as many echocardiograms compared with infants of unexposed
14
15 7 women.⁴³ More frequent echocardiograms could increase the risk of heart defect detection
16
17 8 and give rise to information bias (diagnostic suspicion bias). This bias could partly explain
18
19 9 our findings. On the other hand, more frequent echocardiograms could indicate a more severe
20
21 10 symptomatology among the exposed children due to an unaccounted factor.
22
23
24
25

26 11 Importantly, information on indication for elective termination of pregnancies
27
28 12 was not available in our databases. If pregnant women exposed to an SSRI had a higher rate
29
30 13 of provoked abortions due to severe malformations it could mask a possible teratogenic effect
31
32 14 of the drugs.
33
34
35

36 15 There is a possibility that we have overestimated SSRI treatment periods, since
37
38 16 we cannot adjust for lack of compliance, or the patients' intention of commencing a treatment
39
40 17 shortly after drug redemption. However, it has been estimated that the majority of redeemed
41
42 18 prescriptions by pregnant women are taken⁴⁴, and compliance in Denmark has been estimated
43
44 19 to be 80% for antidepressant treatment during pregnancy.⁴⁵ Furthermore, an overestimation
45
46 20 of treatment periods would bias our estimates towards unity. We performed additional
47
48 21 analyses defining exposure as redemption of 2 SSRI prescriptions during pregnancy. The
49
50 22 results of these analyses, which are not presented, yielded the same statistically significant
51
52 23 association as our primary analyses. Furthermore, we cannot rule out that women defined as
53
54
55

1 pausing their treatment three months before conception were misclassified and had treatment
2 periods reaching into pregnancy. We addressed this issue by increasing the wash-out period
3 before pregnancy and estimating risks for women pausing treatment six and nine months
4 before conception. The results showed similar estimates as for women pausing exposure three
5 months before pregnancy (supplement C).

6 A main strength is the complete national design including nearly all births in
7 Denmark and the mothers' drug redemptions in the study period. The Register of Medicinal
8 Product Statistics includes approximately 97.5% of all redeemed prescriptions.³⁵ Danish
9 pharmacies are, by law, required to register all redeemed prescriptions as part of the national
10 health care reimbursement scheme. All prescriptions have been redeemed and paid for, which
11 increases the probability of exposure. Recall bias is eliminated since information was
12 recorded prospectively and not based on questionnaires or interviews. Furthermore, to our
13 knowledge, this is the first study to address a possible confounding by indication by assessing
14 risks associated with paused exposure to SSRIs during pregnancy.

15 Conclusion

16 Our study shows with high confidence a relation between exposure to an SSRI
17 during the first trimester and risk of congenital malformations of the heart. In addition, we
18 found a nearly identical risk for women who used an SSRI before and after pregnancy but
19 discontinued use during pregnancy. We find both associations strong enough to conclude that
20 risks related to SSRI use during the first trimester are a result of an unaccounted confounder
21 associated to the redemption of an SSRI prescription. This was sustained by the lack of
22 relation between dose and risk. A possible explanation could be information bias, because
23 children of women redeeming an SSRI are more likely to undergo an echocardiogram during

1 the first year of life. However, based on our study's design we cannot rule out an actual
2 causal relation between redemption of an SSRI and congenital malformations. We found no
3 relation with non-SSRI antidepressants, which may indicate a particular risk with SSRIs, but
4 which may also be explained by lack of power.

5 We therefore conclude that the apparent association between SSRI use and
6 congenital malformations of the heart may be confounded by indications. The moderate
7 absolute risk increase combined with uncertainty for causality still requires the risk versus
8 benefit to be evaluated in each individual case.

9 **Acknowledgments**

10 The authors wish to acknowledge the help of Klaus Kähler Holst, Department
11 of Biostatistics at the University of Copenhagen, for contributing with statistical help. None to
12 declare.

13 **Competing interests**

14 All authors declare no support from any organization for the submitted work; no
15 financial relationships with any organizations that might have an interest in the submitted
16 work in the previous three years; no other relationships or activities that could appear to have
17 influenced the submitted work.

18 **Funding**

19 The research project was partially sponsored by the Capital Region of
20 Copenhagen and the Danish Agency for Science, Technology and Innovation.

21

Reference List

- 1
2
3 1
4
5
6 2 (1) Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy:
7
8 3 systematic review. *Obstet Gynecol* 2004;**103**(4):698-709.
9
10
11 4 (2) Chatillon O, Even C. [Antepartum depression: Prevalence, diagnosis and treatment.].
12
13 5 *Encephale* 2010;**36**(6):443-451.
14
15
16
17 6 (3) Ververs T, Kaasenbrood H, Visser G, et al. Prevalence and patterns of antidepressant
18
19 7 drug use during pregnancy. *Eur J Clin Pharmacol* 2006;**62**(10):863-870.
20
21
22 8 (4) Cooper WO, Willy ME, Pont SJ, et al. Increasing use of antidepressants in pregnancy.
23
24 9 *Am J Obstet Gynecol* 2007;**196**(6):544-545.
25
26
27
28 10 (5) Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during
29
30 11 pregnancy: a multisite study. *Am J Obstet Gynecol* 2008;**198**(2):194-195.
31
32
33 12 (6) Alwan S, Reefhuis J, Rasmussen SA, et al. Prevention Study TNBD. Patterns of
34
35 13 Antidepressant Medication Use Among Pregnant Women in a United States
36
37 14 Population. *J Clin Pharmacol* 2011;**51**(2):264-70.
38
39
40 15 (7) Bakker MK, Kolling P, van den Berg PB, et al. Increase in use of selective serotonin
41
42 16 reuptake inhibitors in pregnancy during the last decade, a population-based cohort
43
44 17 study from the Netherlands. *Br J Clin Pharmacol* 2008;**65**(4):600-606.
45
46
47
48 18 (8) Wichman CL, Fothergill A, Moore KM, et al. Recent trends in selective serotonin
49
50 19 reuptake inhibitor use in pregnancy. *J Clin Psychopharmacol* 2008;**28**(6):714-716.
51
52
53
54
55

- 1
2
3 1 (9) Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake
4 inhibitors in pregnancy and the risk of birth defects. *N Engl J Med*
5 2007;**356**(26):2684-2692.
6
7
8
9
10 4 (10) Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-
11 reuptake inhibitors and the risk of birth defects. *N Engl J Med* 2007;**356**(26):2675-
12 2683.
13
14
15
16
17 7 (11) Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk
18 for major congenital anomalies. *Obstet Gynecol* 2011;**118**(1):111-120.
19
20
21
22
23 9 (12) Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. First-trimester use of
24 paroxetine and congenital heart defects: a population-based case-control study. *Birth*
25 *Defects Res A Clin Mol Teratol* 2010;**88**(2):94-100.
26
27
28
29
30
31 12 (13) Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of
32 cardiac malformations in infants: the importance of dosage. *Birth Defects Res B Dev*
33 *Reprod Toxicol* 2007;**80**(1):18-27.
34
35
36
37
38 15 (14) Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the
39 prevalence of congenital malformations. *Pharmacoepidemiol Drug Saf*
40 2007;**16**(10):1075-1085.
41
42
43
44
45
46 18 (15) Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in
47 pregnancy: a prospective, multicentre, controlled, observational study. *Br J Clin*
48 *Pharmacol* 2008;**66**(5):695-705.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 (16) Kallen BA, Otterblad OP. Maternal use of selective serotonin re-uptake inhibitors in
4
5 2 early pregnancy and infant congenital malformations. *Birth Defects Res A Clin Mol*
6
7 3 *Teratol* 2007;**79**(4):301-308.
8
9
10 4 (17) Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake
11
12 5 inhibitors in pregnancy and congenital malformations: population based cohort study.
13
14 6 *BMJ* 2009;**339**:b3569.
15
16
17 7 (18) Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in
18
19 8 pregnancy: an update using Swedish data. *Psychol Med* 2010 Oct;**40**(10):1723-33
20
21
22
23 9 (19) Wichman CL, Moore KM, Lang TR, et al. Congenital Heart Disease Associated With
24
25 10 Selective Serotonin Reuptake Inhibitor Use During Pregnancy. *Mayo Clinic*
26
27 11 *Proceedings* 2009;**84**(1):23-27.
28
29
30
31 12 (20) Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin
32
33 13 reuptake inhibitors and risk of congenital malformations. *Epidemiology*
34
35 14 2006;**17**(6):701-704.
36
37
38
39 15 (21) Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the
40
41 16 prevalence of congenital, specifically cardiac, defects: a meta-analysis of
42
43 17 epidemiological studies. *Birth Defects Res A Clin Mol Teratol* 2010;**88**(3):159-170.
44
45
46 18 (22) Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake
47
48 19 inhibitors in pregnancy. *Obstet Gynecol* 2005;**106**(6):1289-1296.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 (23) Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of
4 the new selective serotonin reuptake inhibitors: a prospective controlled multicenter
5 2 study. *JAMA* 1998;**279**(8):609-610.
6
7
8
9
10
11 4 (24) Ramos E, St-Andre M, Rey E, et al. Duration of antidepressant use during pregnancy
12 and risk of major congenital malformations. *The British Journal of Psychiatry*
13 5 2008;**192**(5):344-350.
14
15
16
17
18 7 (25) Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations in infants
19 following antidepressant exposure in pregnancy: results of a large prospective cohort
20 8 study. *Can J Psychiatry* 2009;**54**(4):242-246.
21
22
23
24
25
26 10 (26) Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations
27 and perinatal events among infants exposed to antidepressant medications during
28 11 pregnancy. *Pharmacoepidemiol Drug Saf* 2007;**16**(10):1086-1094.
29
30
31
32
33
34 13 (27) Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations
35 following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines
36 14 using population-based health data. *Birth Defects Res B Dev Reprod Toxicol*
37 15 2008;**83**(1):68-76.
38
39
40
41
42
43 17 (28) Simon GE, Cunningham ML, Davis RL. Outcomes of Prenatal Antidepressant
44 Exposure. *Am J Psychiatry* 2002;**159**(12):2055-2061.
45
46
47
48
49 19 (29) Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse
50 20 pregnancy outcomes. *Am J Obstet Gynecol* 2006;**194**(4):961-966.
51
52
53
54
55

- 1
2
3 1 (30) Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in
4
5 2 early pregnancy. *Eur J Clin Pharmacol* 1999;**55**(7):503-508.
6
7
8 3 (31) Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant
9
10 4 congenital heart defect. *Reproductive Toxicology* 2006;**21**(3):221-222.
11
12
13 5 (32) Lennestam RM, Kallen BM. Delivery Outcome in Relation to Maternal Use of Some
14
15 6 Recently Introduced Antidepressants. [Article]. *Journal of Clinical*
16
17 7 *Psychopharmacology* 2007;**27**(6):607-613.
18
19
20 8 (33) Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration
21
22 9 System. A cohort of eight million persons. *Dan Med Bull* 2006;**53**(4):441-449.
23
24
25 10 (34) Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Dan Med Bull*
26
27 11 1998;**45**(3):320-323.
28
29
30 12 (35) Sorensen HT, Hansen I, Ejlersen E, et al. Identification of patients treated with strong
31
32 13 analgesics: an assessment of two Danish information systems with respect to
33
34 14 epidemiological research. *J Med Syst* 1996;**20**(1):57-65.
35
36
37 15 (36) Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. *Dan Med Bull*
38
39 16 1997;**44**(4):445-448.
40
41
42 17 (37) Statistics Denmark. Containing detailed statistical information on the Danish Society.
43
44 18 Available at: <http://www.dst.dk/en>. Accessed March, 2012.
45
46
47 19 (38) Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register.
48
49 20 A valuable source of data for modern health sciences. *Dan Med Bull* 1999;**46**(3):263-
50
51 21 268.
52
53
54
55
56
57
58
59
60

- 1
2
3 1 (39) European Surveillance of Congenital Anomalies. EUROCAT Guide 1.3 and reference
4 documents. Newtownabbey Co Antrim: University of Ulster; 2005. Available at:
5
6
7 3 <http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf>. Accessed March
8
9
10 4 2012.
- 11
12
13 5 (40) Fosbol EL, Gislason GH, Jacobsen S, et al. The pattern of use of non-steroidal anti-
14
15 6 inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million
16
17 7 people. *Pharmacoepidemiol Drug Saf* 2008;**17**(8):822-833.
- 18
19
20 8 (41) von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
21
22 9 Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting
23
24 10 observational studies. *Lancet* 2007;**370**(9596):1453-1457.
- 25
26
27
28 11 (42) Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin-reuptake
29
30 12 inhibitors during early pregnancy and risk of congenital malformations: updated
31
32 13 analysis. *Clin Epidemiol* 2010;**2**:29-36.
- 33
34
35
36 14 (43) Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations:
37
38 15 meta-Analysis and consideration of potential confounding factors. *Clin Ther*
39
40 16 2007;**29**(5):918-926.
- 41
42
43 17 (44) de Jong van den Berg LT, Feenstra N, Sorensen HT, et al.. Improvement of drug
44
45 18 exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and
46
47 19 mother as sources for drug exposure data during pregnancy. EuroMAP Group.
48
49 20 European Medicine and Pregnancy Group. *Teratology* 1999;**60**(1):33-36.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 (45) Olesen C, Sondergaard C, Thrane N, et al. Do pregnant women report use of
2 dispensed medications? *Epidemiology* 2001;**12**(5):497-501.

For peer review only

Supplement A. Odds Ratios (OR) and 95% confidence intervals (95% CI) for the incidence and risk of congenital malformations among women exposed to individual SSRIs vs. women with no exposure

	SSRI (n=4183)		Citalopram (n=1606)		Escitalopram (n=293)		Fluoxetine (n=928)		Paroxetine (n=568)		Sertraline (n=817)	
	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a	N (%)	OR (95% CI) ^a
Congenital malformations	208 (4.97)	1.33 (1.16-1.53)	89 (5.54)	89 (5.54-1.51)	8 (2.73)	0.69 (0.34-1.4)	41 (4.42)	1.18 (0.86-1.61)	26 (4.58)	1.25 (0.84-1.85)	44 (5.39)	1.41 (1.03-1.92)
Major	7 (0.17)	1.13 (0.54-2.39)	2 (0.12)	2 (0.12-0.84)	1 (0.34)	2.25 (0.32-16.05)	2 (0.22)	1.44 (0.36-5.79)	1 (0.18)	1.19 (0.17-8.45)	1 (0.12)	0.85 (0.12-6.07)
Of the nervous system	1 (0.02)	0.73 (0.1-5.21)	-	-	0 (0)	-	1 (0.11)	3.22 (0.45-23.03)	0 (0)	-	0 (0)	-
Neural Tube Defects	7 (0.17)	1.43 (0.68-3.01)	5 (0.31)	5 (0.31-2.62)	0 (0)	-	1 (0.11)	0.93 (0.13-6.63)	0 (0)	-	1 (0.12)	1.05 (0.15-7.45)
Of the eye	2 (0.05)	2.36 (0.58-9.61)	0 (0)	-	0 (0)	-	0 (0)	-	1 (0.18)	8.32 (1.16-59.81)	1 (0.12)	6.13 (0.85-44.05)
Of the ear, face and neck	77 (1.84)	2.01 (1.6-2.53)	28 (1.74)	28 (1.74-1.91)	3 (1.02)	1.06 (0.34-3.3)	17 (1.83)	2.05 (1.27-3.31)	8 (1.41)	1.54 (0.77-3.1)	21 (2.57)	2.73 (1.75-4.26)
Of the heart	49 (1.17)	2.04 (1.53-2.72)	17 (1.06)	17 (1.06-1.86)	2 (0.68)	1.12 (0.28-4.51)	9 (0.97)	1.73 (0.89-3.33)	6 (1.06)	1.89 (0.85-4.23)	15 (1.84)	3.09 (1.82-5.25)
Septal defects	21 (0.5)	1.62 (1.05-2.5)	7 (0.44)	7 (0.44-1.41)	0 (0)	0 (0-0)	3 (0.32)	1.03 (0.33-3.2)	2 (0.35)	1.13 (0.28-4.54)	9 (1.1)	3.6 (1.86-6.96)
Ventricular septal defects	34 (0.81)	2.6 (1.84-3.68)	12 (0.75)	12 (0.75-2.41)	1 (0.34)	1.01 (0.14-7.23)	7 (0.75)	2.53 (1.2-5.32)	6 (1.06)	3.51 (1.57-7.87)	8 (0.98)	2.85 (1.35-5.99)
Atrial septal defects	2 (0.05)	1.25 (0.31-5.02)	0 (0)	-	1 (0.34)	8.71 (1.21-62.64)	0 (0)	-	0 (0)	-	1 (0.12)	3.22 (0.45-23.03)
Atrioventricular septal	7 (0.17)	1.41 (0.67-2.98)	2 (0.12)	2 (0.12-1.03)	1 (0.34)	2.66 (0.37-19.02)	1 (0.11)	0.94 (0.13-6.67)	1 (0.18)	1.52 (0.21-10.8)	2 (0.24)	2.09 (0.52-8.38)
Of the respiratory system	6 (0.14)	1.02 (0.46-2.27)	4 (0.25)	4 (0.25-1.8)	0 (0)	-	1 (0.11)	0.76 (0.11-5.4)	0 (0)	0 (0-0)	1 (0.12)	0.88 (0.12-6.24)
Oro-facial clefts	13 (0.31)	1.8 (1.04-3.12)	7 (0.44)	7 (0.44-2.5)	0 (0)	-	2 (0.22)	1.25 (0.31-5)	2 (0.35)	2.09 (0.52-8.39)	2 (0.24)	1.43 (0.36-5.74)
Of the digestive system	1 (0.02)	1.04 (0.14-7.44)	1 (0.06)	1 (0.06-2.54)	0 (0)	-	0 (0)	-	0 (0)	-	0 (0)	-
Abdominal wall defects	11 (0.26)	0.84 (0.45-1.57)	9 (0.56)	9 (0.56-2.02)	0 (0)	-	0 (0)	-	0 (0)	-	2 (0.24)	0.44 (0.06-3.11)
Of the internal urinary system	19 (0.45)	1.55 (0.99-2.44)	8 (0.5)	8 (0.5-1.7)	1 (0.34)	1.08 (0.15-7.67)	3 (0.32)	1.09 (0.35-3.38)	6 (1.06)	3.83 (1.71-8.57)	1 (0.12)	0.41 (0.06-2.93)
Of the external genital organs	53 (1.27)	0.93 (0.71-1.23)	24 (1.49)	24 (1.49-1.13)	1 (0.34)	0.25 (0.04-1.75)	10 (1.08)	0.76 (0.41-1.42)	7 (1.23)	0.91 (0.43-1.92)	11 (1.35)	1 (0.55-1.81)
Of the limbs	8 (0.19)	1.29 (0.64-2.59)	3 (0.19)	3 (0.19-1.25)	1 (0.34)	2.18 (0.31-15.57)	2 (0.22)	1.46 (0.36-5.85)	1 (0.18)	1.2 (0.17-8.55)	1 (0.12)	0.83 (0.12-5.9)
Of the musculoskeletal system	7 (0.17)	1.57 (0.74-3.31)	1 (0.06)	1 (0.06-0.59)	0 (0)	-	1 (0.11)	0.97 (0.14-6.92)	3 (0.53)	4.65 (1.49-14.53)	2 (0.24)	2.35 (0.59-9.45)
Chromosomal abnormalities												

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	9	1.36	4	4	0	-	4	3.08	0	-	1	0.88
Other malformations	(0.22)	(0.68-2.74)	(0.25)	(0.25-1.32)	(0)	-	(0.43)	(1.15-8.23)	(0)	-	(0.12)	(0.12-6.28)
	2	2.78	1	1	0	-	0	-	0	-	1	10.13
And teratogenic syndromes	(0.05)	(0.67-11.6)	(0.06)	(0.06-3.58)	(0)	-	(0)	-	(0)	-	(0.12)	(1.36-75.44)
	1	0.39	0	-	0	-	1	1.79	0	-	0	-
Genetic syndromes	(0.02)	(0.06-2.78)	(0)	-	(0)	-	(0.11)	(0.25-12.76)	(0)	-	(0)	-

Incidence is presented as number of cases (N) with percentages (%). Estimates of multivariable logistic regressions are presented as Odds Ratios (OR) with 95% confidence intervals (95% CI) ^aMultivariable logistic regressions are adjusted for mother’s age, parity, income, education, smoking and year of conception.



Supplement B. Risk of congenital malformations among women exposed to an SSRI vs. women with no exposure further adjusted for co-medication.

Outcome	Exposed to any SSRI				No exposure
	First trimester N=4183		Paused during pregnancy N=806		N=843 797
	N (%)	OR (96% CI)	N (%)	OR (96% CI)	N (%)
Major malformations	208 (4.97)	1.32 (1.14-1.52)	36 (4.47)	1.27 (0.91-1.77)	29703 (3.52)
Congenital malformations of the heart	77 (1.84)	1.98 (1.57-2.49)	13 (1.61)	1.84 (1.06-3.19)	7755 (0.92)
Septal defects	49 (1.17)	2.00 (1.50-2.67)	11 (1.36)	2.54 (1.40-4.62)	4826 (0.57)
Ventricular septal defects	21 (0.50)	1.58 (1.02-2.44)	9 (1.12)	3.71 (1.92-7.17)	2803 (0.33)
Atrial septal defects	34 (0.81)	2.54 (1.79-3.60)	6 (0.74)	2.60 (1.16-5.81)	2490 (0.30)
Congenital malformations of the digestive system	13 (0.31)	1.74 (1.00-3.02)	1 (0.12)	0.74 (0.10-5.29)	1545 (0.18)
Congenital malformations of the internal urinary system	11 (0.26)	0.86 (0.46-1.60)	-	-	2333 (0.28)
Congenital malformations of the external genital organs	19 (0.45)	1.53 (0.97-2.41)	2 (0.25)	0.89 (0.22-3.57)	2504 (0.30)
Congenital malformations of the limbs	53 (1.27)	0.93 (0.71-1.22)	14 (1.74)	1.36 (0.80-2.31)	11785 (1.40)

Estimates are presented as Odds Ratios (OR) with 95% confidence intervals (95% CI). Multivariable logistic regressions are adjusted for mother's age, parity, income, education, smoking, year of conception and co-medication with psycholeptics and antidiabetics.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Supplement C. Adjusted odds Ratios (OR) and 95% confidence intervals (95% CI) for association between congenital malformations among women pausing SSRI treatment three, six or nine months before pregnancy

Outcome	Three months (n=806)		Six months (n=681)		Nine months (n=441)	
	N (%)	OR (95% CI)	N (%)	OR (95% CI)	N (%)	OR (95% CI)
Major malformations	36 (4.47)	1.27 (0.91-1.78)	29 (4.26)	1.21 (0.83-1.75)	19 (4.31)	1.22 (0.77-1.93)
Congenital malformations of the heart	13 (1.61)	1.85 (1.07-3.20)	12 (1.76)	2.02 (1.14-3.57)	8 (1.81)	2.07 (1.03-4.17)
Septal defects	11 (1.36)	2.56 (1.41-4.64)	10 (1.47)	2.73 (1.46-5.09)	6 (1.36)	2.52 (1.12-5.64)
Ventricular septum defects	9 (1.12)	3.74 (1.93-7.23)	8 (1.17)	3.90 (1.94-7.85)	4 (0.91)	3.00 (1.12-8.04)
Atrial septum defects	6 (0.74)	2.61 (1.17-5.84)	5 (0.73)	2.55 (1.05-6.14)	3 (0.68)	2.35 (0.75-7.31)
Congenital malformations of the digestive system	1 (0.12)	0.75 (0.11-5.35)	1 (0.15)	0.90 (0.13-6.41)	1 (0.23)	1.41 (0.2-10.01)
Congenital malformations of the internal urinary system	-	-	-	-	-	-
Congenital malformations of the external genital organs	2 (0.25)	0.89 (0.22-3.59)	-	-	-	-
Congenital malformations of the limbs	14 (1.74)	1.37 (0.80-2.32)	11 (1.62)	1.26 (0.70-2.30)	7 (1.59)	1.23 (0.58-2.60)

Estimates are presented as Odds Ratios (OR) with 95% confidence intervals (95% CI). Multivariable logistic regressions are adjusted for mother's age, parity, income, education, smoking and year of conception.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	7,8
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9,10
		(b) Indicate number of participants with missing data for each variable of interest	8
		(c) Summarise follow-up time (eg, average and total amount)	-
Outcome data	15*	Report numbers of outcome events or summary measures over time	9,10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-16
		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	13
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14-16
Discussion			
Key results	18	Summarise key results with reference to study objectives	16,17
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16-21
Generalisability	21	Discuss the generalisability (external validity) of the study results	21
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.